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Abstract 
Mitochondria are responsible for some of the cell’s most fundamental biological pathways 
and metabolic processes, including aerobic ATP production by the mitochondrial respiratory chain. 
In humans, mitochondrial dysfunction can lead to severe disorders of energy metabolism, which are 
collectively referred to as mitochondrial disorders and affect approximately 1:5,000 individuals. 
These disorders are clinically heterogeneous and can affect multiple organ systems, often within a 
single individual. Symptoms can include myopathy, exercise intolerance, hearing loss, blindness, 
stroke, seizures, diabetes, and GI dysmotility. Mutations in over 150 genes in the mitochondrial 
DNA (mtDNA) and nuclear genome are known to cause mitochondrial diseases and an additional  
~1,000 nuclear-encoded mitochondrial proteins have the potential to underlie mitochondrial 
disorders but have not yet been linked to human disease. As a result, determining a molecular 
diagnosis for patients with suspected mitochondrial disorders remains a challenge.  
To improve our understanding of the genetic basis of mitochondrial disorders, we have 
developed a “Mito-Exome” sequencing approach that targets the mtDNA and the exons of nearly 
1600 nuclear-encoded genes implicated in mitochondrial function, mitochondrial disease, or 
monogenic disorders with phenotypic overlap. We have applied this method to a diverse set of 102 
patients referred to Massachusetts General Hospital with clinical and/or biochemical suspicion of 
mitochondrial disease. In addition to identifying pathogenic mutations in genes previously known to 
cause mitochondrial disease (e.g. NDUFV1, POLG2), our study has implicated several new or 
unexpected genes, including WFS1, HSD17B4, DPYD, and ATP5A1. However, the genetic basis of 
disease remains unclear for the majority of our patients. Our study demonstrates the strengths and 
limitations of next-generation sequencing approaches for the molecular diagnosis of suspected 
mitochondrial disorders.  
To infer the function of uncharacterized mitochondrial proteins implicated in our genetic 
studies, we have also developed a computational genomic approach utilizing protein homology and 
bacterial gene neighborhoods. This approach has implicated the uncharacterized protein C6orf57 in 
a role in succinate dehydrogenase, also known as Complex II of the mitochondrial respiratory chain. 
The computational and genomic approaches described in this dissertation seek to improve our 
understanding of mitochondrial biology and its relationship to human health and disease.
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CHAPTER I: 
 
Introduction 
 
he Human Genome Project produced a draft of the entire human genome in 2001 and was 
officially completed in 2003. At a cost of roughly $3 billion and a length of 13 years, this 
project altered the course of scientific discovery and laid the foundations for a new future in 
medicine.1 Today, the advent of new sequencing technologies has enabled the sequencing of whole 
genomes for less than $10,000 – and this cost continues to drop. These new sequencing capabilities 
have transformed scientific research and have begun to make genomic medicine a reality. 
For my dissertation, I have focused on a subset of the human genome pertaining to the 
mitochondrion, the organelle known to many as the “powerhouse of the cell”. As my adviser, Dr. 
Vamsi Mootha, determined years ago, mitochondria are, in many ways, the perfect organelle, 
especially as a focus for scientific research and medical discovery. The mitochondrion is a contained 
system within the cell, can be physically isolated, and much is known about its biology and the 
biology of its bacterial ancestors. The study of mammalian mitochondria has the potential to 
significantly improve our understanding of human health and disease, as mitochondrial dysfunction 
T 
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has been associated with nearly every disease state, including both rare diseases and common ones, 
including diabetes, cancer, and Parkinson’s disease. 2    
Through my dissertation research, I have sought to gain insight into the genetic basis of 
mitochondrial dysfunction and into the biological roles of uncharacterized mitochondrial proteins. 
This introduction reviews the basic biology of the mitochondrion, discusses the role of 
mitochondria in human health and disease, and outlines the subsequent chapters. 
 
Mitochondria: the powerhouse of the cell 
Mitochondria are energy-producing organelles found in most eukaryotic species. In 
mammalian cells, mitochondria are responsible for producing over 80% of cellular energy, in the 
form of adenosine triphosphate (ATP). It is widely accepted that mitochondria derived from a 
bacterial ancestor whose close symbiosis with a host cell eventually led to the complete integration 
of the two organisms.3 Over the course of evolution, the genes encoded by the mitochondrial 
genome were either lost or transferred to eukaryotic host genome, such that today only 13 of the 
1,500 estimated human mitochondrial proteins are encoded by the mitochondrial DNA (mtDNA). 
The closest existing relative to the ancestor of mitochondrial appears to be Rickettsia prowazekii, an 
intracellular alpha-proteobacteria.4 Approximately 60% of mammalian mitochondrial proteins have 
close bacterial homologues,5 enabling researchers to infer the function of many mitochondrial 
proteins from their bacterial counterparts. 
The mitochondrial proteome consists of approximately 1,000-1,500 proteins, which are 
encoded by both the mitochondrial and nuclear genomes. The mitochondrial genome, or mtDNA, 
is maternally inherited and encodes 13 proteins in addition to the 22 transfer RNAs (tRNAs) and 2 
ribosomal RNAs (rRNAs) required for their translation.6 The remaining proteins are encoded by the 
nuclear genome and inherited, as other nuclear-encoded genes, in an autosomal, X-linked, or Y-
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linked manner. Although mtDNA is essential to mitochondrial function, the proteins needed to 
replicate, transcribe, and translate the mtDNA are all encoded in the nuclear genome. Through an 
integrative Bayesian approach, members of the Mootha laboratory have created MitoCarta, a 
compendium of 1013 human mitochondrial proteins estimated to be over 85% complete and 
containing roughly 10% false positives. 5 This effort has systematically catalogued the pathways and 
metabolic processes that occur within the mitochondria and has identified numerous proteins of 
unknown function that operate within the organelle.  
The mitochondrion’s primary role, arguably, is the creation of energy in the form of ATP 
through the mitochondrial respiratory chain.7 Through a process called oxidative phosphorylation 
(OXPHOS), the mitochondrial respiratory chain couples electron transport across four complexes 
(Complexes I-IV) to ATP creation by ATP synthase (Complex V). Complex I, also known as 
NADH dehydrogenase, mediates transfer of electrons from NADH to coenzyme Q (CoQ), also 
known as ubiquinone. Complex II, also known as succinate dehydrogenase, mediates transfer of 
electrons from succinate to CoQ without pumping protons. Complex III, also known as ubiquinol-
cytochrome c reductase, transfers electrons from reduced CoQ to cytochrome c. Complex IV, also 
known as cytochrome c oxidase, transfers electrons from cytochrome c to oxygen, forming water. 
Complexes I, III, and IV couple electron transport to the pumping of proteins out of the 
mitochondrial matrix, forming a proton gradient. This gradient is then dissipated by Complex V, 
also known as ATP synthase, a molecular motor that couples the flow of protons back into the 
mitochondrial matrix to the creation of ATP. 
The mitochondrion is also host to numerous pathways and metabolic reactions, including 
the tricarboxylic acid (TCA) cycle, fatty acid catabolism, branched chain amino acid catabolism, and 
parts of heme biosynthesis. Although many of these pathways ultimately feed into the respiratory 
chain, other metabolic reactions may be independent of the primary role of mitochondria in ATP 
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synthesis. For an overview of the mitochondrion and mitochondrial research, see the book “Power, 
Sex, Suicide: Mitochondria and the Meaning of Life” by Nick Lane. 8  
 
Mitochondrial disorders 
Given the role of the mitochondrion in cellular metabolism, it is not surprising that 
mitochondrial dysfunction can lead to devastating disorders of energy metabolism in humans. 
Mitochondrial respiratory chain diseases, collectively the most common inborn error of metabolism, 
are a large group of rare disorders that are notorious for their phenotypic and genetic 
heterogeneity.9-11 The defining feature of these disorders is a biochemical defect in oxidative 
phosphorylation (OXPHOS). These disorders affect an estimated 1:5,000 births,12 and can present in 
infancy or adulthood with varying levels of phenotypic severity. Multiple organ systems can be 
affected, with features that can include myopathy, seizures, lactic acidosis, sensorineural deafness, 
optic atrophy, diabetes mellitus, liver failure, seizures, and ataxia.9, 10 Mitochondrial disorders can be 
caused by mutations in the nuclear or mitochondrial genomes and over 100 genetic loci have been 
identified to date.13, 14  
Although these disorders may be inherited in a maternal, recessive, X-linked, or dominant 
fashion, many are singleton cases with no obvious family history of the disorder.15-17 Due to high 
pleiotropy and locus heterogeneity, traditional sequential genetic testing – including mitochondrial 
DNA (mtDNA) point mutation analysis and Sanger sequencing of nuclear-encoded disease genes – 
results in molecular diagnoses for only a fraction of patients.18 The limitations in traditional genetic 
testing have thus motivated the recent development of new next-generation sequencing (NGS)-
based tools19-23 and commercially available tests that simultaneously evaluate panels of genes 
previously shown to cause mitochondrial disorders. 
          5 
In addition to causing inborn errors of metabolism, mitochondrial dysfunction has been 
directly linked to cancer. Germline mutations in subunits and assembly factors of succinate 
dehydrogenase, also known as Complex II of the mitochondrial respiratory chain, are associated 
with hereditary paraganglioma and pheochromocytoma, which are rare neuroendocrine tumors.24 
Additionally, germline mutations of fumarate hydratase are responsible for hereditary 
leiomyomatosis and renal-cell cancer (HLRCC).25 Although tumor syndromes of a mitochondrial 
origin are discussed in Chapter V, this dissertation is primarily focused on mitochondrial disorders 
of energy metabolism that manifest as neurological or multi-system disorders. 
 
Diagnosis of Mitochondrial Disease 
Despite all we know, diagnosing a mitochondrial disease remains challenging due to the 
clinical and genetic heterogeneity of the disease.26 The current diagnostic algorithms integrate 
biochemical, histological, clinical, and metabolic features to assess the likelihood of the disease. For 
example, elevated lactate and alanine are markers for mitochondrial dysfunction. A number of 
biochemical tests can be performed from skin, muscle, or liver biopsy, including testing of specific 
enzymatic reactions (e.g. pyruvate dehydrogenase, respiratory chain Complexes I-IV). Histological 
findings indicative of a mitochondrial disorder include ragged-red-fibers and abnormal 
mitochondrial morphology. Depletion of or deletions within mitochondrial DNA are also evidence 
of mitochondrial dysfunction, although mtDNA deletions can naturally accumulate with age. 27 
There are two major diagnostic algorithms used by neurologists to diagnose patients 
suspected of a mitochondrial disorder, specifically respiratory chain (RC) disorders. The Bernier 
criteria,28 which are applicable to adults and children, rely heavily on biochemical testing of the RC 
enzymes in muscle or liver biopsy. The algorithm lists a number clinical, histological, metabolic, 
enzymological, or genetic features that satisfy “major” or “minor” criteria. Depending on the 
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number of major and minor criteria, the patient is then classified as “unlikely”, “possible”, 
“probable”, or “definite”. The Morava criteria, 11 designed for the diagnosis of pediatric patients, rely 
more heavily on clinical observation (Figure 1.1). The algorithm consists of tallying up the number 
of muscular, central nervous system, and multi-systemic clinical features along with the number of 
metabolic/imaging or histologic abnormalities suggestive of mitochondrial disease, according to a 
pre-specified formula. The patient is given a score between 1-12 designating the likelihood of a 
mitochondrial disorder, with 1 translating to “unlikely, 2 to 4 as “possible”, 5 to 7 as “probable”, and 
8 to 12 as “definite”. 
  With the exception of Coenzyme Q10 (CoQ10), there are currently no FDA-approved 
treatments for mitochondrial diseases, 29 and therefore medical management is limited to treatment 
of symptoms (e.g. seizures, diabetes) as well as to the “mito-cocktail”, a combination of cofactors 
and vitamins, including Coenzyme Q, known to play a role in mitochondrial function. Still, the 
diagnosis of a mitochondrial disease can be important, in that it ends an often time-consuming and 
expensive diagnostic odyssey, informs medical management, and enables patients to seek the proper 
patient advocacy and support groups and to enroll in clinical trials. 
Genetic diagnosis of mitochondrial diseases, like all monogenic disorders, has traditionally 
been on a gene-by-gene basis through the use of Sanger sequencing or variant genotyping (e.g. 
restriction fragment length polymorphism [RFLP] analysis). However, recent technologies (“next-
generation” or “massively parallel” sequencing) have enabled the sequencing of many DNA 
fragments simultaneously at a dramatically lower cost per base compared to Sanger sequencing. 
These technologies have revolutionized the molecular diagnosis of genetic disorders.  
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Figure 1.1. Morava criteria for the clinical diagnosis of mitochondrial disease in children 
Adopted from Morava et al. (2006).11
A. Muscular presentation  
     (max. 2 points) 
Ophthalmoplegia* 
Facies myopathica 
Exercise intolerance 
Muscle weakness 
Rhabodmyolysis 
Abnormal EMG 
 
B. CNS presentation 
     (max. 2 points) 
Developmental delay 
Loss of skills 
Stroke-like episode 
Migraine 
Seizure 
Myoclonus 
Cortical blindness 
Pyramidal signs 
Extrapyramidal signs 
Brainstem involvement 
C. Multisystem disease 
     (max. 3 points) 
Hematology 
GI tract 
Endocrine/growth 
Heart 
Kidney 
Vision 
Hearing 
Neuropathy 
Recurrent/familial 
II. Metabolic/imaging studies 
     (max 4 points) 
Elevated lactate* 
Elevated L/P ratio 
Elevated alanine*  
Elevated CSF lactate 
Elevated CSF protein 
Elevated CSF alanine*  
Urinary TA excretion* 
Ethylmalonic aciduria 
Stroke-like picture/MRI 
Leigh syndrome/MRI* 
Elevated lactate/MRS 
III. Morphology 
      (max 4 points) 
Ragged red/blue fibers** 
Cox-negative fibers** 
Reduced COX staining** 
Reduced SDH staining 
SDH positive blood vessels* 
Abnormal mitochondria/EM* 
 *  = 2 points 
** = 4 points  
GI, gastrointestinal; L/P, lactate/pyruvate; COX, cytochrome c oxidase; SDH, succinate 
dehydrogenase; EM, electron microscopy; EMG, electromyography; TA, tricarboxylic acid 
Score: 
0 to 1: mitochondrial disorder unlikely  
2 to 4: possible mitochondrial disorder  
5 to 7: probable mitochondrial disorder 
8 to 12: definite mitochondrial disorder 
I.! Clinical signs and symptoms, 1 point/symptom  
        (max 4 points) 
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Next-generation sequencing 
Although there are a number of next-generation sequencing (NGS) technologies that are 
currently available, this dissertation primarily focuses on the technology developed by Solexa, which 
was acquired by Illumina in 2007. For an overview and history of the various next-generation 
sequencing technologies, see “The $1,000 Genome” by Kevin Davies. 30   
The principle behind Illumina’s technology is massively parallel sequencing-by-synthesis. 31 
DNA fragments to be sequenced are immobilized on glass slides. Each DNA fragment is clonally 
amplified, such that there are millions of spatially separated colonies of PCR products. Sequencing 
occurs base-by-base through the addition of four fluorescently-labeled, reversibly terminated 
nucleotides. After each round of synthesis the clusters are excited by a laser, emitting a color 
(captured by a camera) that identifies the newly added base. The fluorescent label and blocking 
group are then removed, allowing for the addition of the next base and this process is repeated for 
N cycles, reading N base pairs from both ends of the PCR fragments, with N typically ranging from 
76-150. In this way, millions of DNA fragments are sequenced in parallel.  
Next-generation sequencing technologies are often used downstream of methods that 
facilitate targeted capture of particular regions of genomic DNA. Most commonly, this targeted 
capture is used to target the exome, the 1% of the human genome that encodes exons of protein-
coding genes. The process of targeted exome capture followed by NGS is therefore referred to as 
“exome sequencing”. More generally, targeted DNA capture followed NGS is referred to as 
“targeted sequencing”. Although targeted sequencing is highly efficient, the approach impairs the 
detection of certain types of variants, including structural variants, which are better detected through 
whole-genome sequencing. 
Since 2009, targeted sequencing has been used to identify the genetic basis of disease in 
patients suspected of rare, monogenic disorders.32 The first two examples of the successful 
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application of this technology were from the labs of Richard Lifton and Jay Shendure.33, 34 In fact, 
the Shendure study implicated the gene DHODH, which encodes dihydroorotate dehydrogenase, a 
mitochondrial enzyme involved in de novo pyrimidine biosynthesis. Since these landmark papers, 
exome sequencing has become more commonplace; in 2012 there were 739 papers published with 
“exome” in the title or abstract, an average of two per day. 
 
Next-generation sequencing of mitochondrial disorders 
These sequencing technologies have greatly expanded our understanding of the genetic basis 
of mitochondrial diseases. Since 2011, there have been over 40 papers describing cases in which 
exome sequencing led to a genetic diagnosis of a patient with mitochondrial disease. Although some 
papers describe cases that expand the phenotypic spectrum of a known genetic disorder,35 many of 
these papers identify causal mutations in genes not previously associated with human disease.36-38 In 
a number of cases (AGK, FOXRED1), genetic studies led to fundamentally new knowledge of 
protein function, in addition to having diagnostic implications. 22, 39 The combination of previously 
established mitochondrial disease genes with ones newly discovered through high throughput 
sequencing technologies has led to a total of over 150 genes (35 mtDNA, 128 nDNA) associated 
with mitochondrial disorders (Figure 1.2). This list of genes and their associated phenotypes is 
critical for genetic diagnosis of suspected mitochondrial disorders.  
Although exome sequencing is a powerful method, it does not target the mtDNA and was 
initially more expensive than targeting a smaller, custom set of genomic regions. For these reasons, 
our laboratory developed a targeted “MitoExome” sequencing approach for the molecular diagnosis 
of mitochondrial disease.39 This approach targeted the entire 16kb mtDNA, as well as the exons of 
~1000 MitoCarta proteins. Later iterations included an additional ~400 proteins with predicted links 
to mitochondrial biology as well as ~200 genes known to cause metabolic or neurological disorders 
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with phenotypic overlap to mitochondrial disease. Sample preparation, sequencing and data 
processing were performed at Massachusetts General Hospital (MGH) or Broad Institute. 
In work prior to this dissertation, our lab benchmarked the approach in a set of 42 severe, 
infantile cases with biochemically-proven mitochondrial disease in whom traditional approaches had 
failed to provide a molecular diagnosis.39 MitoExome sequencing enabled new molecular diagnoses 
in 24% of cases and identified an additional 29% with recessive mutations in candidate genes not 
previously linked to disease. Pathogenicity of three of these candidate genes has since been 
independently validated,23, 37, 40 suggesting that that the diagnostic success rate will rise once the 
pathogenicity of additional genes is established. Extrapolating to all such cases with or without prior 
molecular diagnoses, we estimated that MitoExome sequencing would enable diagnosis in 47% of 
cases and prioritize candidates in a further 20%.39  
It remained unclear, however, how such a diagnostic approach would fare when applied 
more broadly to patients ascertained on the basis of clinical presentation. To answer this question, 
members of our laboratory performed MitoExome sequencing in 102 patients referred to the 
metabolic disorders registry at Massachusetts General Hospital. Patients were suspected of 
mitochondrial disorders based on clinical, biochemical, and/or molecular findings, and had clinical 
presentations ranging from mild to severe, with varying age of onset. The results of this study are 
detailed in Chapter II.  
For two of these patients, we were surprised to identify presumably causal genetic defects in 
non-mitochondrial proteins. The first patient, described in Chapter III, was an adult male who 
presented with diabetes mellitus, diffuse brain atrophy, autonomic neuropathy, optic nerve atrophy, 
a severe amnestic syndrome, and heteroplasmic mtDNA deletions. The second patient, described in 
Chapter IV, was an adult male with cerebellar ataxia, peripheral neuropathy, mild hearing loss, 
azoospermia, and mild reductions in mitochondrial respiratory chain activity. 
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Figure 1.2. Mitochondrial and nuclear genes implicated in mitochondrial disorders.  
Gene list compiled by S. Vafai and S. Calvo. Abbreviations: mtDNA, mitochondrial DNA; nuDNA, 
nuclear DNA 
ATP6
ATP8
COX1
COX2
CYTB
ND1
ND2
ND3
ND4
ND4L
ND5
ND6
12S rRNA
tRNAAla
tRNAArg
tRNAAsn
tRNAAsp
tRNACys
tRNAGln
tRNAGlu
tRNAGly
tRNAHis
tRNAIle
tRNALeu1
tRNALeu2
tRNALys
tRNAMet
tRNAPhe
tRNAPro
tRNASer1
tRNASer2
tRNAThr
tRNATrp
tRNATyr
tRNAVal
mtDNA (35)
AARS2
ABCB7
ACAD9
ACO2
ADCK3
AFG3L2
AGK
AIFM1
ANT1
ATP5E
ATPAF2
BCS1L
BOLA3
C10orf2
C12orf65
C19orf12
CLPP
COA5
COQ2
COQ6
COQ9
COX10
COX14 
COX15
COX4I2
COX6B1
DARS2
DGUOK
DNA2
DNAJC19
DNM1L
EARS2
ETHE1
FARS2
FASTKD2
FOXRED1
FXN
GARS
GCDH
GFER
GFM1
GLRX5
HARS2
HCCS
HSPD1
ISCU
LARS2
LRPPRC
MARS2
MFN2
MPV17
MRPL3
MRPL44 
MRPS16
MRPS22
MTFMT
MTO1
MTPAP
NDUFA1
NDUFA10
NDUFA11
NDUFA12
NDUFA2
NDUFA9
NDUFAF1
NDUFAF2
NDUFAF3
NDUFAF4
NDUFAF5 
NDUFAF6 
NDUFB3
NDUFB9
NDUFS1
NDUFS2
NDUFS3
NDUFS4
NDUFS6
NDUFS7
NDUFS8
NDUFV1
NDUFV2
NFU1
NUBPL
OPA1
PDK3
PDSS1
PDSS2
PNPT1
POLG
POLG2
PUS1
RARS2
RMND1
RRM2B
SARS2
SCO1
SCO2
SDHA
SDHAF1
SDHAF2
SDHB
SDHC
SDHD
SERAC1
SLC19A3 
SLC25A1 
SLC25A3
SPG7
ST3GAL5
SUCLA2
SUCLG1
SURF1
TACO1
TAZ
TIMM8A
TK2
TMEM70
TRMU
TSFM
TTC19
TUFM
TYMP
UQCRB
UQCRC2 
UQCRQ
YARS2
nuDNA (126)
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While Chapters I-IV describe efforts to pinpoint the genetic basis of disease in patients and 
to discover new disease genes, my research has also focused on developing methods to elucidate the 
function of uncharacterized mitochondrial proteins. Such methods have important implications for 
basic science as well as for clinical genetic studies, by helping to identify candidate genes related to a 
particular pathway or by informing the interpretation of variants in uncharacterized genes.     
Chapter V describes an approach using bacterial operons and protein homology to infer the 
function of uncharacterized mitochondrial proteins. This approach has identified a putative 
functional relationship between the uncharacterized protein C6orf57 and Complex II of the 
mitochondrial respiratory chain. 
 Finally, Chapter VI describes the implications of my dissertation work and future directions. It 
is my hope that the research presented here facilitates the genetic diagnosis of rare disorders and 
accelerates future investigations of mitochondrial function in human health and disease. 
          13 
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Abstract 
Objective: To evaluate the utility of targeted exome sequencing for the molecular diagnosis of 
mitochondrial disorders, which exhibit marked phenotypic and genetic heterogeneity.  
Methods: We considered a diverse set of 102 patients with suspected mitochondrial disorders based 
on clinical, biochemical, and/or molecular findings, and whose disease ranged from mild to severe, 
with varying age of onset. We sequenced the mitochondrial genome (mtDNA) and the exons of 
1598 nuclear-encoded genes implicated in mitochondrial biology, mitochondrial disease, or 
monogenic disorders with phenotypic overlap. We prioritized variants likely to underlie disease and 
established molecular diagnoses in accordance with current clinical genetic guidelines.  
Results: Targeted exome sequencing yielded molecular diagnoses in 22% of cases, including 17/18 
(94%) with prior molecular diagnoses and 5/84 (6%) without. The five new diagnoses implicated 
two genes associated with canonical mitochondrial disorders (NDUFV1, POLG2), and three genes 
known to underlie other neurological disorders (DPYD, KARS, WFS1), underscoring the 
phenotypic and biochemical overlap with other inborn errors. We prioritized variants in an 
additional 26 patients, including recessive, X-linked, and mtDNA variants that were enriched two-
fold over background and await further support of pathogenicity. In one case, we modeled patient 
mutations in yeast to provide evidence that recessive mutations in ATP5A1 can underlie combined 
respiratory chain deficiency.  
Conclusion: The results demonstrate that targeted exome sequencing is an effective alternative to 
the sequential testing of mtDNA and individual nuclear genes as part of the investigation of 
mitochondrial disease. Our study underscores the ongoing challenge of variant interpretation in the 
clinical setting. 
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Introduction 
itochondrial disorders are a heterogeneous collection of rare disorders caused by 
mitochondrial dysfunction.1 Multiple organ systems can be affected, with features that can 
include myopathy, encephalopathy, seizures, lactic acidosis, sensorineural deafness, optic atrophy, 
diabetes mellitus, liver failure, and ataxia.2 Mitochondrial disorders can be caused by mutations in the 
nuclear or mitochondrial genomes and over 100 genetic loci have been identified to date.3, 4 While 
these disorders may be inherited in a maternal, recessive, X-linked, or dominant fashion, many cases 
have no obvious family history of the disorder.5-7 Due to phenotypic and locus heterogeneity, 
traditional sequential genetic tests result in molecular diagnoses for only a fraction of patients.8 
Limitations in traditional genetic testing have motivated our group and others to develop “next-
generation sequencing” (NGS) approaches for molecular diagnosis.9-12 
Previously, we developed a targeted “MitoExome” sequencing approach for the molecular 
diagnosis of mitochondrial disease and benchmarked its performance in a cohort of 42 severe, 
infantile cases with biochemically-proven mitochondrial respiratory chain disease.13 MitoExome 
sequencing enabled new molecular diagnoses in 24% of cases and, in an additional 29% of cases, 
identified recessive candidate disease genes, three of which have since been independently 
validated.14-16 Here, we evaluate a similar approach in a collection of 102 patients with suspicion of 
mitochondrial disease, spanning a broad range of age and phenotypic severity. 
 
Subjects and Methods 
Subjects 
We considered patients that were referred to the MGH Mitochondrial Disorders Clinic for 
evaluation of possible mitochondrial disease and enrolled in the Partners DNA and Tissue 
Repository for Molecular Studies in Disorders of Energy Metabolism during 2004-2011. Of the 159 
M 
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unrelated cases for whom high quality DNA was available, we selected the 102 subjects with the 
highest clinical suspicion of mitochondrial disease, based on chart review and review of biochemical 
testing results. The selected cases included as positive controls all 18 patients with prior molecular 
diagnoses acquired through traditional genetic testing (13 mtDNA and 5 nuclear mutations), eleven 
of which were made prior to referral to MGH. The remaining 84 patients had no prior molecular 
diagnosis, despite varying degrees of genetic testing in 74 cases. Of the 102 selected cases, 75% had 
histological studies, 63% had blood metabolite studies, 33% had neuroimaging studies, and 68% had 
enzyme analysis of the electron transport chain (ETC) from muscle biopsy. Muscle biopsies were 
not typically performed in cases with prior molecular diagnoses.  
 
Standard Protocol Approvals, Registrations, and Patient Consents  
Study protocols were approved by the Partners Human Research Committee. All samples 
were obtained with informed consent for sequence analysis and data deposition into public 
databases. 
 
MitoExome Sequencing and Variant Detection 
We expanded our previously reported MitoExome sequencing protocol to include additional 
genes of interest (Appendix A-1). Specifically, we targeted 3.1Mb of DNA including the mtDNA 
and coding exons of 1598 nuclear-encoded genes (Table A-1): 113 genes known to cause 
mitochondrial disease, 945 high-confidence mitochondrial genes from MitoCarta,17 327 genes 
predicted to associate with mitochondrial function, and 213 genes underlying monogenic disorders 
in the differential diagnosis (DDx), i.e. metabolic and neurological disorders with phenotypic 
similarity to mitochondrial disease. DNA was extracted from whole blood or Epstein-Barr virus 
immortalized lymphoblastoid cell lines (LBLs). Targeted DNA regions were captured18 and 
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sequenced (paired-end 76bp reads, Illumina GA-IIx or Hi-Seq)18, 19 at the MGH Next-Generation 
Sequencing Core. Sequence alignment, variant detection and annotation were performed as 
described in Appendix A-1. mtDNA variants with ≥1% heteroplasmy based on read count were 
identified, and confirmatory qPCR assays were performed at m.3243, m.8344, and m.8993 (Baylor 
College of Medicine, test 3006). 
 
Variant Prioritization 
We prioritized the following mtDNA variants: (i) confirmed pathogenic variants in 
MITOMAP,20 with allele frequency (AF) <0.5% in mtDB21 (ii) mtDNA deletions/rearrangements 
detected through de novo mtDNA assembly,13 and (iii) loss-of-function (i.e. nonsense or frameshift) 
mutations with AF<0.3% in mtDB21 and present in <10% of 102 cases. Variants with heteroplasmy 
<20% were confirmed in an independent DNA sample or were considered prioritized variants of 
unknown significance. 
We prioritized the following nuclear variants: (i) known pathogenic variants (Human Gene 
Mutation Database 22 version 2010.3) with AF<1% in 1000 Genomes Project23 (low coverage release 
20110511), and (ii) variants with AF<0.5% that were likely deleterious, including nonsense, splice 
site, coding indel, and missense variants at sites conserved in ≥10 of 44 aligned vertebrate species.13 
For established autosomal recessive disease genes, we required presence of homozygous or two 
heterozygous variants. For X-linked recessive disease genes, we required two variants in females or a 
hemizygous variant in males. Nuclear variants in candidate genes not previously linked to disease 
were prioritized as above but considered to be prioritized variants of unknown significance. For 
dominant disease genes (autosomal or X-linked), we required AF<0.1%. All prioritized variants were 
manually reviewed to remove likely sequencing artifacts and to phase potential compound 
heterozygous variants (Appendix A-1). Prioritized variants are listed in Table A-2. 
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Estimating the Background Frequency of Variants 
mtDNA was analyzed in 284 healthy individuals of European descent with whole-genome 
data from the 1000 Genomes Project. Nuclear DNA was analyzed in 371 healthy individuals of 
European descent with whole-exome data from the NIMH Control Sample repository. Background 
frequency comparisons were limited to sequence regions well covered in all individuals, as previously 
described.13 Enrichment was calculated as the percent of cases versus controls containing at least 
one qualifying variant, with significance assessed by a one-tailed binomial exact test. 
 
Modeling the ATP5A1  Mutation in Yeast  
The S. cerevisiae atp1 null mutant was created in an ade2- background and transformed with 
the pRS305 plasmid expressing wild-type or mutant alleles of ATP1 (Appendix A-1). Mitochondrial 
membrane potential, phosphate/oxygen (P/O) ratio, respiratory control rate (RCR), and ATPase 
activity were measured as described.24 Petite frequency (percent white colonies, where lack of red 
pigment in ade2- strains indicates mtDNA loss/deletion) was assessed in single haploid colonies 
grown, plated, and incubated in YPD, as previously described.24 Loss of mtDNA in petite colonies 
was confirmed via mating with a ρ0 strain. 
 
Data Availability 
Sequence and phenotype data are available in dbGaP, accession phs000339.  
 
Results 
MitoExome Sequencing in 102 patients 
MitoExome sequencing was applied to 102 MGH patients suspected of a mitochondrial 
disorder. The cohort represented a broad spectrum of phenotypic severity ranging from lethal, 
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infantile to mild, adult-onset disease (Figure 2.1). Likelihood of mitochondrial disease was assessed 
as “definite”, “probable” or “possible” based on the Bernier and Morava criteria.25, 26 51% of 
patients had a biochemical ETC defect in muscle, defined as ≤30% of normal activity of any 
complex after normalization to citrate synthase activity. 11% had positive family history, defined as 
presence of a first-degree relative with a highly similar phenotype. Age at diagnosis, defined as the 
date of initial biochemical or genetic testing for a mitochondrial disorder, ranged from 0 to 64, with 
median 27 years. 67% of patients were female and 87% were of European descent.  
The approach yielded extremely high sequence coverage with mean 226X at targeted nuclear 
sites and 12,680X at mtDNA sites (Table A-3). 95% of targeted bases were covered with at least 10 
reads, enabling confident detection of variants at the majority of sites. The deep coverage of 
mtDNA enabled sensitive detection of known heteroplasmic variants, including 5/6 variants present 
at <10% heteroplasmy (Appendix A-2).  
We reasoned that high confidence “molecular diagnoses” could only be established within 
genes proven to cause disease consistent with the patient’s phenotype. We therefore first examined 
variants in established disease loci, adopting guidelines from the American College of Medical 
Genetics (ACMG) to make new molecular diagnoses.27 Prioritized variants not consistent with 
previously reported phenotypes, or prioritized variants in genes not previously implicated with 
disease, were designated “prioritized variants of unknown significance” (pVUS). 
 
Diagnoses in mtDNA 
Within mtDNA, we prioritized previously reported pathogenic variants, large deletions or 
rearrangements, and rare loss-of-function variants (Methods). Other rare missense and tRNA 
variants were not prioritized, as their collective frequency could not be distinguished from that 
observed in healthy individuals (Figure A-1). 
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Figure 2.1. Characteristics of 102 MGH Patients Suspected of Mitochondrial Disease 
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Our diagnostic procedure correctly recovered molecular diagnoses for 12/13 patients with 
previously identified pathogenic mtDNA mutations (Table A-4). The exception was a patient with 
m.3243A>G present at 3% heteroplasmy based on qPCR in the sequenced LBL sample, 
underscoring the importance of tissue selection in studies of mitochondrial disease.28 
No confident mtDNA diagnoses were established in the remaining individuals. However, we 
identified six patients with pVUS in mtDNA (Appendix A-2, Table A-5), representing a 2.5-fold 
excess over the background rate in healthy controls (p<0.05). 
 
Diagnoses in Previously Established Nuclear Disease Genes 
We next prioritized nuclear variants within 113 genes known to underlie mitochondrial 
disease and 213 genes underlying monogenic disorders in the differential diagnosis. Our diagnostic 
procedure recovered the prior molecular diagnoses for 5/5 cases with pathogenic nuclear mutations 
(Table A-6), and established new molecular diagnoses in five patients (Table 2.1). 
Two of the five new molecular diagnoses implicated genes underlying primary mitochondrial 
disorders: a heterozygous POLG2 mutation known to be pathogenic29, 30 was detected in an 
individual with PEO, and compound heterozygous mutations in NDUFV131 were detected in an 
individual with complex I deficiency in whom prior NDUFV1 sequencing had detected only one 
variant.  
The other three new molecular diagnoses, described below, implicated autosomal recessive 
variants in genes known to cause monogenic disorders in the differential diagnosis: 
dihydropyrimidine dehydrogenase (DPD) deficiency (DPYD),32 Wolfram syndrome (WFS1),33 and a 
Charcot-Marie-Tooth-like axonal neuropathy (KARS).34 Importantly, the phenotypes of these 
patients were not clearly discernible even in retrospect from the rest of the cohort, underscoring the 
phenotypic and biochemical overlap between canonical mitochondrial disease and other monogenic 
disorders.  
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Table 2.1. Individuals with New Molecular Diagnoses from MitoExome Sequencing. 
Abbreviations: PEO, progressive external ophthalmoplegia; IUGR, Intrauterine growth restriction; 
COX, cytochrome oxidase; sib, affected sibling; ↓↓, <20% activity, ↓, 20-30% activity relative to 
citrate synthase; -, not determined; EM, electron microscopy; LM, light microscopy; cmpd. het., 
compound heterozygous; hom., homozygous; na, not applicable; * gene not previously linked to 
disease 
 
ID Sex 
Age of 
Onset 
(Death) 
Clinical Features 
Family 
History 
ETC Biochemistry mtDNA/ 
Histology 
Defects 
Gene Type 
Mutation 
[Reference] 
ACMG 
Category 
Disease Assoc. 
with Gene 
(OMIM) I I+III II III IV 
1004 F 1 yr 
Stroke, exercise intolerance, 
dyspnea, leukodystrophy, 
headache 
1 sib 
(Leigh’s 
disease) 
d. 13 mo 
↓↓ ↓↓  - ↓ 
EM: 
subsarcolemmal mito. 
aggregates, curvilinear 
cristae 
NDUFV1 
cmpd. 
het. 
 
p.P113L 
p.S158PfsX15 
 
3 
2 
Complex I 
deficiency 
(#252010) 
1019 F 44 yr Bi-lateral ptosis, PEO, ataxia, fatigue, dysphagia 
3 sibs 
(PEO) - - - - - 
LM: ragged red fibers,  
COX neg. fibers POLG2 het. 
p.R369G 
[29] 
1 
 
PEO, autosomal 
dominant 4 
(#610131) 
1073 M 33 yr 
Diabetes mellitus type 1, 
memory loss, cerebellar atrophy, 
autonomic dysfunction, mild 
hearing loss 
None      Heteroplasmic mtDNA deletions WFS1 hom. 
p.R558C 
[38] 
1 
 
Wolfram 
syndrome 
(#222300) 
1097 F 4 yr 
Toe walking, tremors, myoclonic 
jerks, falls, extrapyramidal 
spasticity, dystonia, fatigue 
None  ↓↓    
EM: accumulation of 
pleomorphic, 
subsarcolemmal 
mitochondria 
DPYD hom. IVS14+1G>A [32] 
1 
 
Dihydro-
pyrimidine 
dehydrogenase 
deficiency 
(#274270) 
1098 M 6 mo (3 yr) 
Hypotonia, global 
developmental delay, hearing 
loss, strabismus, 
ophthalmoplegia, dystonia 
None    -  Increased mtDNA: 187% (muscle) KARS 
cmpd. 
het. 
p.T587M 
p.P228L 
3 
3 
Charcot-Marie-
Tooth disease 
(#613641) 
1020 F Newborn (3 mo) 
Failure to thrive, microcephaly, 
encephalopathy, IUGR, 
hypotonia, bacteremia, 
pulmonary hypertension,  
heart failure 
1 sib 
(hypotonia, 
microcephaly, 
seizures) 
d. 15 mo 
 ↓↓   ↓ 
mtDNA depletion: 
42% (muscle)  
39% (liver) 
ATP5A1* hom. p.Y321C 3 na 
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Patient 1097, of Indian descent, developed multiple neurological symptoms starting at age 
four, including toe walking, tremors, and dystonia. Muscle tissue showed reduced complex I+III 
activity and electron microscopy showed accumulation of pleomorphic subsarcolemmal 
mitochondria, some with complex cristae. Sequencing revealed a homozygous splice mutation in 
DPYD previously associated with recessive DPD deficiency and 5-fluorouracil (5-FU) toxicity.32, 35 
The diagnosis of DPD deficiency was confirmed by subsequent urine tests that showed highly 
elevated uracil (395 mmol/mol creatinine; reference range <28) and thymine (300 mmol/mol 
creatinine; reference range <6). 
Patient 1073, of Ashkenazi ancestry, presented with type 1 diabetes at age 33 and developed 
autonomic dysfunction, cerebellar atrophy, and severe memory loss. Muscle biopsy showed 
heteroplasmic mtDNA deletions. MitoExome sequencing revealed a homozygous missense 
mutation in WFS1 underlying Wolfram syndrome, which was not detected by initial clinical gene 
sequencing, as previously described.4 
Patient 1098, of European descent, presented at six months of age with developmental delay, 
hypotonia, ophthalmoplegia, and other neurological manifestations (Table 2.1), and died by age four. 
EEG and MRI were unremarkable, however brain stem auditory evoked potential study at 10 
months was markedly abnormal, suggesting severe peripheral conduction defects in the auditory 
pathways bilaterally. Metabolic studies showed elevated plasma alanine (657 umol/L; reference range 
142-421) and CSF lactate (2.4 mmol/L; reference range 0.5-2.2); increased mtDNA levels were 
found in muscle (187% of controls). Sequencing revealed compound heterozygous missense 
mutations in KARS, which encodes both the cytoplasmic and mitochondrial lysyl-tRNA synthetase 
(Figure A-2). Although formal experimental proof is needed, given the predicted severity of the 
mutations at highly conserved residues and the previous report of recessive KARS mutations in 
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patients with overlapping symptoms, the observed mutations are likely to underlie our patient’s 
phenotype, as discussed in Appendix A-2. 
In addition to five new molecular diagnoses, 11 patients harbored pVUS in established 
nuclear disease loci (Appendix A-2): seven in recessive-acting genes (four-fold enrichment over 
background frequency, p<0.05), and four in dominant-acting genes (no enrichment over 
background) (Methods). 
Together, analysis of over 300 established disease loci in the mitochondrial and nuclear 
genome recovered the diagnoses of 17/18 patients with prior molecular diagnoses and led to new 
molecular diagnoses in 5/84 previously unsolved cases (Figure 2.2).  
 
Parental sequencing 
To assess whether de novo mutations could be a major contributor to sporadic disease, we 
performed MitoExome sequencing on parental DNA from five probands without family history of 
disease. No confirmed de novo mutations were identified. 
 
Prioritized Recessive and X-linked Variants in Genes Not Previously Linked to Disease 
We next explored whether disease-causing mutations may lie in 1283 nuclear-encoded 
candidate genes associated with the mitochondrion but not previously linked to disease.  
If candidate genes truly underlie disease, we might expect an increased number of predicted 
deleterious variants in patients compared to healthy individuals (Figure A-3). We observed modest 
two-fold enrichment for likely recessive variants (p<0.05) and seven-fold enrichment for 
hemizygous X-linked variants in male patients (p<0.01). No significant enrichment was observed for 
prioritized heterozygous variants, X-linked variants in females, or synonymous variants. 
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Figure 2.2. MitoExome Sequencing in 102 Patients with Suspected Mitochondrial Disease 
Number of patients with molecular diagnoses or prioritized variants of unknown significance 
(pVUS), with the prioritized loci listed at right. Patients who harbored multiple variants were 
annotated based on their highest priority variant, with all additional pVUS listed in brackets. 
Parentheses indicate number of patients. Underline indicates experimental support of pathogenicity.  
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Altogether, 17 candidate genes not previously linked to mitochondrial disease harbored 
autosomal recessive or hemizygous X-linked variants (Figure 2.2, Table A-5). We emphasize that 
due to the modest enrichment over background, only a subset is expected to be causal. Further 
genetic and experimental studies are needed to establish pathogenicity. 
 
Pathogenicity of ATP5A1 Mutations in a Yeast Model  
In one such case, we investigated prioritized variants detected in an infantile patient with 
combined oxidative phosphorylation (OXPHOS) deficiency and mtDNA depletion (Figure 2.3). 
Patient 1020, born to consanguineous first-cousin parents of Moroccan descent, presented at birth 
with microcephaly, pulmonary hypertension and heart failure requiring extracorporeal membrane 
oxygenation, hypotonia, hyperalaninemia, and bacteremia. She died at the age of three months. 
Muscle tissue showed decreased ETC activity (22% complex I+III and 30% complex IV activity) 
and mtDNA depletion (42% of controls in muscle, 39% in liver). The patient had one healthy sister 
and one sister who died at 15 months with a similar clinical presentation and combined OXPHOS 
deficiency in muscle, consistent with a recessive disorder. 
MitoExome sequencing revealed a homozygous ATP5A1:c.962A>G (p.Y321C) variant, 
which was not present in 1000 Genomes nor EVS, and introduced a missense mutation at a residue 
evolutionary conserved to bacteria. The variant was homozygous in the affected sister and 
heterozygous in their mother. DNA from the father and unaffected sister were unavailable. The only 
other homozygous variant prioritized in the proband (HAO2:p.D259E) did not segregate with 
disease in the family.  
Since cultured patient fibroblasts did not survive lentiviral transduction required for human 
complementation studies, we modeled the ATP5A1:p.Y321C mutation in yeast. This mutation lies 
within a highly conserved region of the protein associated with mitochondrial genomic integrity (mgi)  
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Figure 2.3. Modeling ATP5A1  Mutations in Yeast  
(A) Family pedigree and genotype at ATP5A1:c.962A>G. (B) ETC biochemistry and mtDNA 
quantitation in muscle. (C) Schematic of ATP5A1 protein, with sequence alignment shown in inset 
Vertical bars indicate patient mutation (red) and yeast mitochondrial genome integrity (mgi) 
mutations (black). (D) Yeast atp1 deletion strains show normal (red) and petite (white) colonies. (E) 
Mitochondrial physiology of yeast deletion strains report mean values +/- standard deviation across 
three replicates. * p<0.01, one-tailed t-test; Abbreviations: na, not available; nd, not determined; d., 
deceased; ↓↓, <20%, ↓, 20-30% activity relative to citrate synthase. 
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in yeast; nearby mutations result in decreased coupling of the ATP synthase and lead to a high rate 
of mtDNA loss (Figure A-4).24 We expressed the analogous yeast variant (ATP1:p.Y315C) in an atp1 
knockout strain and observed a three-fold increase in petite frequency, reflective of the rate of 
mtDNA loss, and a two-fold decrease of mitochondrial membrane potential (p<0.01, t-test) 
compared to expression of wild-type ATP1, consistent with reported mgi mutants.24  
Collectively, the familial segregation, severe amino acid change of a highly conserved residue, 
and increased rate of mtDNA loss in a yeast model consistent with the patient phenotype strongly 
support the pathogenicity of this ATP5A1 mutation. 
 
Predictors of Diagnostic Efficacy 
We investigated whether any patient features correlated with the rate of diagnostic success, 
including family history, age-of-onset, and ETC deficiency. We observed significant enrichment of 
molecular diagnoses only in cases with clear family history (Table A-7). 
 
Cohort Comparison  
Lastly, we compared the rate of molecular diagnosis from this study and our previous 
sequencing study of 42 infants with severe, biochemically-proven OXPHOS disease.13 We limited 
the analysis to cases without prior molecular diagnoses, and only focused on the subset of 1,034 
genes that were analyzed in both studies.13 Compared with the infantile cohort, the 84 MGH 
patients suspected of mitochondrial disorders contained markedly fewer new diagnoses and 
prioritized recessive variants in mitochondrial proteins not yet linked to disease (Figure 2.4). Similar 
differences were observed when considering all patients, including those with prior molecular 
diagnoses (Figure A-5).  
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Figure 2.4. New Molecular Diagnoses and Prioritized Recessive Genes 
Comparison of MitoExome analysis from our (A) previous study13 and (B) current study, showing 
the fraction of patients with firm molecular diagnoses (dark blue) and autosomal recessive candidate 
genes (light blue). Comparison is restricted to the subset of patients who lacked molecular diagnosis 
prior to MitoExome sequencing and to the 1,034 genes analyzed in both studies (thereby excluding 
212 DDx genes from the current study). 
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Discussion 
We assessed the efficacy of targeted NGS for molecular diagnosis in 102 patients suspected 
of a mitochondrial disorder, providing new molecular insights into the genetic basis of 
mitochondrial disease and lessons for incorporating NGS in the clinic. Unlike our previous study of 
biochemically-proven infantile cases, the current study includes many patients with late-onset 
presentations and uncertain clinical diagnoses. MitoExome sequencing recovered 94% of prior 
molecular diagnoses and yielded molecular diagnoses for 7% of patients refractory to traditional 
genetic testing, less than a third the diagnostic success rate (24%) observed in our previous study.13 
Two major possibilities exist to explain the lower yield. First, milder cases may be due not to severe, 
recessive, coding mutations, but perhaps due to variants with incomplete penetrance, regulatory 
variants, or genetic interaction of weaker alleles. Second, a subset of our MGH patients may not 
actually have primary mitochondrial disease, despite clinical and biochemical features used in 
standard diagnostic algorithms.  
It is notable that two proteins implicated in disease localize outside of mitochondria, which 
may help delineate pathways of cross-talk between mitochondria and other cellular compartments. 
Mutations in WFS1, a protein localized to the endoplasmic reticulum, have been previously linked 
with mtDNA deletions.36 DPYD, a cytosolic enzyme in pyrimidine metabolism also responsible for 
catabolism of the chemotherapeutic drug 5-FU, has not been linked to mitochondrial function, but 
defects in two adjacent metabolic enzymes cause mtDNA depletion syndromes: TYMP (OMIM 
#603041) and TK2 (OMIM #609560). Further studies are needed to explore whether mitochondrial 
defects are typical in DPD deficiency. 
Our study identified 26 patients with prioritized variants of unknown significance in known 
or candidate disease genes. In one case, we provide evidence that recessive mutations in ATP5A1, 
the alpha subunit of the F1-Fo ATP synthase, can underlie combined OXPHOS deficiency. This is 
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the second nuclear-encoded complex V subunit linked to disease.37 Our study suggests that 
mutations in this complex may have a secondary impact on mtDNA homeostasis and the respiratory 
chain (Appendix A-2). 
A number of lessons have emerged from our study that may be useful as NGS is introduced 
into the clinic. First, targeted exome sequencing is a cost-effective and time-efficient alternative to 
traditional, sequential testing of the mtDNA and individual nuclear genes. For a subset of patients, a 
firm molecular diagnosis can be established quickly in a minimally invasive manner. Prospective 
studies will be required to determine the efficacy of such technology as a first-line diagnostic test. 
Second, our study underscores the phenotypic overlap between mitochondrial disorders and other 
genetic syndromes, and as costs drop, argues for whole exome or whole genome sequencing. Third, 
when possible we advocate familial sequencing to facilitate phasing of haplotypes, detection of de 
novo variants, and filtering of candidate variants. Fourth, our study underscores the need for 
guidelines for interpretation of NGS data for mitochondrial disorders. Larger databases of healthy 
and morbid genomes will aid in future interpretation, and to this end, our data has been deposited 
into dbGaP. Finally, DNA sequence must not be interpreted alone, but rather in the context of the 
broader clinical picture. Principled methods combining genomic, biochemical, and clinical data will 
be required to usher NGS into the clinical arena. 
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Abstract 
Background: Mitochondrial diseases comprise a diverse set of clinical disorders that affect multiple 
organ systems with varying severity and age of onset. Due to their clinical and genetic heterogeneity, 
these diseases are difficult to diagnose. We have developed a targeted exome sequencing approach 
to improve our ability to properly diagnose mitochondrial diseases and apply it here to an individual 
patient. Our method targets mitochondrial DNA (mtDNA) and the exons of 1,600 nuclear genes 
involved in mitochondrial biology or Mendelian disorders with multi-system phenotypes, thereby 
allowing for simultaneous evaluation of multiple disease loci. 
Case Presentation: Targeted exome sequencing was performed on a patient initially suspected to 
have a mitochondrial disorder. The patient presented with diabetes mellitus, diffuse brain atrophy, 
autonomic neuropathy, optic nerve atrophy, and a severe amnestic syndrome. Further work-up 
revealed multiple heteroplasmic mtDNA deletions as well as profound thiamine deficiency without a 
clear nutritional cause. Targeted exome sequencing revealed a homozygous c.1672C>T (p.R558C) 
missense mutation in exon 8 of WFS1 that has previously been reported in a patient with Wolfram 
syndrome. 
Conclusion: This case demonstrates how clinical application of next-generation sequencing 
technology can enhance the diagnosis of patients suspected to have rare genetic disorders. 
Furthermore, the finding of unexplained thiamine deficiency in a patient with Wolfram syndrome 
suggests a potential link between WFS1 biology and thiamine metabolism that has implications for 
the clinical management of Wolfram syndrome patients.
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Introduction 
itochondrial diseases are a clinically heterogeneous set of disorders that are caused by 
defects in mitochondria, the organelles responsible for producing most of the cellular ATP 
in humans 1. Multiple organ-systems are typically affected in these disorders, with neurologic and 
myopathic features being the most prominent 2. Common clinical features of mitochondrial disease 
include skeletal myopathy accompanied by exercise intolerance, cardiomyopathy, sensorimotor 
peripheral polyneuropathy, sensorineural deafness, optic atrophy, diabetes mellitus, seizures, and 
ataxia 3. These disorders can be caused by mutations in the nuclear or mitochondrial genomes, and 
over 100 loci have been identified to date 4.  
The clinical and genetic heterogeneity of mitochondrial diseases as well as the technical 
difficulty of assessing mitochondrial function create a significant diagnostic challenge 5. One major 
source of cost and time delays in the clinical evaluation of patients with suspected mitochondrial 
disease is the use of sequential genetic tests to evaluate individual disorders; as such, a systematic 
genetic test could accelerate the diagnostic process and reduce overall cost. In the present report, we 
describe a suspected case of mitochondrial disease whose diagnosis of Wolfram syndrome was 
ultimately revealed through targeted exome sequencing. 
 
Case Presentation 
In January 2008, a 61-year-old man with a history notable for diabetes mellitus (DM), 
autonomic neuropathy, diffuse brain atrophy, optic nerve atrophy (OA), and profound amnesia was 
referred to us to establish neurologic care. The patient carried a diagnosis of multiple system 
atrophy- cerebellar type (MSAc), principally because of severe cerebellar and brainstem atrophy on 
MRI. 
 
M 
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The patient’s early history was remarkable only for childhood bedwetting and urinary 
urgency as a young adult. He was otherwise well during this time and was a talented athlete who 
completed college and practiced as an accountant. In his early 20s, he developed bladder dysfunction 
of unclear etiology requiring intermittent straight catheterization, as well as erectile dysfunction.  
At age 33, he was diagnosed with DM, presumed to be type 1, and began treatment with 
insulin therapy. Although there is no biochemical data available from the time of his original 
diagnosis, recent testing demonstrated a random C-peptide level of 0.6 ng/mL (reference range 0.9 
to 4.3 ng/mL) at a time when his blood glucose was 83 mg/dL. He takes an average of 24 units of 
insulin per day, and has had good glycemic control with hemoglobin A1c measurements ranging 
between 6.5 and 7.2% over the last several years. He has had no evidence of retinopathy, or other 
microvascular or macrovascular complications. He had polyuria and polydipsia at the time of his 
initial DM diagnosis, but these symptoms resolved once he initiated insulin therapy.  
The patient began dressing in strange colors in his 30s, and color blindness was ultimately 
diagnosed in his 40s. At age 53, the patient presented for a routine screening ophthalmology exam 
and was discovered to have bilateral OA with preserved vision. Brain MRI at that time revealed 
severe atrophy of the cerebellar hemispheres and vermis, pons, and middle cerebellar peduncles as 
well as moderate cerebral atrophy; a more recent study at age 61 showed these findings as well as 
more severe cerebral atrophy (Figure 3.1). Despite these radiographic findings, the patient and his 
wife reported no gait instability or upper extremity incoordination.  
During his late 50s, the patient’s neurologic status deteriorated. Formal neuropsychological 
evaluation revealed profound anterograde amnesia, with additional impairments in cognitive 
flexibility, executive function, naming, and high order visual processing skills. Attention span, mental 
tracking, verbal abstract reasoning, complex auditory instructions, and visual spatial functions were 
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Figure 3.1. MRI at age 61 demonstrating severe atrophy of the cerebral hemispheres, cerebellum, 
and brainstem. A-F: 3-D SPGR coronal MRI; G,H: T1 sagittal MRI; I-L: FLAIR axial MRI, showing 
white matter signal hyperintensities. 
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preserved. From a psychiatric perspective, he developed symptoms of depression, which responded 
to treatment with sertraline.  
In parallel with the decline in his memory, the patient also developed progressive autonomic 
neuropathy, with gastroparesis and severe postural hypotension. The autonomic dysfunction 
exceeded what might be expected from his diabetes mellitus, given his good glycemic control and 
the absence of other diabetic complications. His bladder dysfunction worsened and he required 
suprapubic catheter placement at the age of 61. Due to his multiple functional deficits, the patient 
became unable to work and is now completely reliant upon his wife for care.  
Regarding his family history, the patient was born to Ashkenazi Jewish parents and there was 
no parental consanguinity. His mother died from melanoma, and his father died from multiple 
strokes and a myocardial infarction. He has two adult daughters, one of whom has attention deficit 
hyperactivity disorder (ADHD) and Tourette syndrome, while the other suffers from chronic 
urinary tract infections. His maternal grandmother had type 2 DM, and a maternal first cousin had 
type 1 DM. No other close relatives have suffered from endocrine, psychiatric, or neurologic 
disease. 
On physical examination, he appeared generally medically well. He weighed 79 kilograms 
and was 178 cm tall, yielding a body mass index of 25. Postural hypotension was evident with 
systolic blood pressure falling from 150 to 95 after one minute of standing, though asymptomatic. 
Funduscopic examination revealed optic atrophy bilaterally with no sign of diabetic retinopathy. 
Visual acuity was 20/40 in each eye. Pupil responses to light and accommodation were normal. Eye 
movements were normal with the exception of saccadic intrusion into horizontal smooth pursuit. 
Clinical examination revealed high tone hearing loss bilaterally. Audiometry demonstrated moderate 
sensorineural hearing loss in the high frequencies on the left, and mild sensorineural hearing loss in 
the mid-frequencies on the right sloping to a severe loss in the high frequencies (Figure 3.2). Word 
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recognition was excellent in both ears; 98% on the right and 96 % on the left. Muscle tone in the 
extremities was normal, bulk was intact, and strength was full. There was no evidence of dysmetria 
with finger-to-nose and heel-to-shin testing, and gait was slow but stable. His affect was flat and he 
was passive throughout the interview, speaking only when spoken to. He was not oriented to time or 
place. He could repeat four words, but could not learn them despite multiple attempts. He was 
unable to provide information concerning major current political or national news. He could, 
however, recall sizable fragments of remote memory from his college years.  
The absence of the cerebellar motor syndrome and the presence of a profound amnestic 
syndrome on examination called the patient’s diagnosis of MSAc into question 6, and we undertook 
re-evaluation of his case to explore alternate diagnoses. His laboratory work-up revealed an 
undetectable thiamine level, a surprising finding given his normal diet and the absence of alcohol 
abuse. We ascribed his amnestic disorder to presumed long-standing thiamine deficiency, but 
repletion produced minimal clinical impact. The involvement of multiple systems suggested the 
possibility of a mitochondrial disorder. Genetic testing for OPA1, MELAS, MERFF, LHON and 
NARP were negative, however analysis of mitochondrial DNA (mtDNA) from a muscle biopsy 
sample by both Southern blotting and PCR analysis revealed multiple heteroplasmic deletions. 
Biochemical testing revealed a minor defect in complex I of the electron transport chain. COX and 
SDH staining of the muscle biopsy specimen were unremarkable, and the mitochondria appeared 
grossly normal on electron microscopic examination. Occasional central vacuoles and tubular 
aggregates were seen in the myocytes, which were felt to be consistent with a mild non-specific 
myopathy.  
Given the diagnostic uncertainty and concern for a mitochondrial disorder, the patient was 
enrolled in the mitochondrial disease registry at Massachusetts General Hospital. As part of this 
program, a sample of the patient’s DNA from whole blood underwent targeted exome 
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Figure 3.2. Results of audiometric testing at age 61 conforming to ANSI 1969 standards. 
ANSI=American National Standards Institute; dB=decibel; Hz=hertz; PTA=pure tone average.  
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("MitoExome") sequencing. Mitochondrial DNA and the exons of 1,600 nuclear genes either 
encoding mitochondrial proteins or implicated in Mendelian disorders with multi-system phenotypes 
were targeted using hybrid selection 7. Amplified targets were sequenced on the Illumina GAIIx 
platform. Rare, protein-modifying variants found to be homozygous or potentially compound 
heterozygous were prioritized (Figure 3.3), revealing an X-linked functional polymorphism 
c.937G>T (p.D313Y) in GLA that is not considered pathogenic 8 and a homozygous c.1672C>T 
(p.R558C) missense mutation in exon 8 of WFS1 that has previously been reported in a patient with 
Wolfram syndrome 9. No heteroplasmic mtDNA deletions were detected in whole blood. The 
patient’s WFS1 mutation was verified through Sanger sequencing in a CLIA-certified laboratory, 
though not without complications; the initial report came back negative and only after requested 
follow-up was the homozygous mutation detected, thereby confirming the diagnosis of Wolfram 
syndrome. 
 
Discussion and Conclusions 
Wolfram syndrome (OMIM #222300) is an autosomal recessive disorder also known as 
DIDMOAD for its typical clinical features of Diabetes Insipidus, Diabetes Mellitus, Optic Atrophy 
and Deafness.10 The minimum criteria for the diagnosis of Wolfram syndrome are the presence of 
diabetes mellitus and optic atrophy, both of which usually occur by the age of fifteen.11 The disorder 
is also associated with diverse neurologic and psychiatric symptoms, including cognitive 
impairment.12 Though with genetic data in hand the diagnosis of Wolfram syndrome now seems 
clear for the patient presented here, his late age of onset and the prominence of his amnesia are 
quite atypical for this syndrome and made the diagnosis seem less likely. Furthermore, the clinical 
presentation, mtDNA deletions, and biochemical data were highly suggestive of a mitochondrial 
disorder.  
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Figure 3.3. Results of MitoExome sequencing. Rare, protein-modifying variants were prioritized, 
revealing a homozygous c.1672C>T (p.R558C) missense mutation in exon 8 of WFS1 that has 
previously been reported in a patient with Wolfram syndrome. 9 
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Given the multiple organ system dysfunction characteristic of Wolfram syndrome, it was 
initially thought by a number of clinicians to be a bona fide mitochondrial disorder 13. Further 
supporting this hypothesis was the observation of mtDNA deletions in some patients with Wolfram 
syndrome 14-16. However, in 1998 two groups identified WFS1, which encodes an 890 amino acid 
trans-membrane protein localized to the endoplasmic reticulum, as the gene responsible for the 
majority of Wolfram syndrome cases, thereby arguing against a mitochondrial etiology 17, 18. 
Mechanistic studies of WFS1 have revealed an important role in dampening the ER stress response 
in pancreatic beta cells and neurons, and loss of the gene has been shown to result in an exaggerated 
stress response and accelerated cell death 19. However, given the shared clinical features between 
Wolfram syndrome and many mitochondrial disorders, as well as the presence of mtDNA deletions 
in some patients, many unanswered questions remain about the biology of WFS1 and its impact on 
mitochondrial function and mtDNA maintenance.  
Mutations in residue 558 of WFS1, as identified in the patient described here, have been 
previously reported. Our patient’s p.R558C mutation was first reported as a heterozygous variant in 
a cohort of psychiatric patients, though it is unclear whether the variant contributed to disease 
pathogenesis in that population 20. Our patient’s p.R558C mutation, as well as a p.R558H mutation, 
have been reported in multiple patients with Wolfram syndrome 9, 21, 22. Exome databases suggest 
that the allele frequency of WFS1 c.1672C>T (p.R558C) is quite rare; specifically, the variant is not 
found in the 1,000 Genomes Project 23 nor in over 2,500 publicly available European and African 
American exomes 24.  
Chaussenot et al. specifically discuss the phenotype of a Wolfram case with the same 
p.R558C mutation identified in our patient in compound heterozygosity with a p.F354del frameshift 
mutation 12. Like our patient, Chaussenot et al.’s case had significant cerebellar atrophy by MRI, 
neurogenic bladder symptoms, dementia, DM, OA, as well as the absence of diabetes insipidus. 
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However, unlike our patient, the compound heterozygote case had earlier onset of DM, OA, and 
neurologic symptoms (at ages 9, 10, and 27 respectively), lacked hearing impairment, and developed 
cerebellar ataxia and nystagmus as part of her neurologic presentation. Of note, the profound 
amnestic syndrome seen in our patient was not reported for the compound heterozygote case, and is 
atypical for Wolfram syndrome patients in general. These cases demonstrate that phenotypic 
heterogeneity is present even among patients with similar mutations, likely attributable to different 
genetic and environmental backgrounds.  
Some WFS1 mutations have been suggested to function in an autosomal dominant manner 
yielding symptoms such as optic atrophy and hearing impairment in a heterozygous state 25, 26. The 
patient has one daughter who struggled with Tourette syndrome and ADHD, but the family history 
is otherwise unremarkable, with no close family members suffering from symptoms associated with 
Wolfram syndrome. No familial DNA was available to determine the carrier status of his daughter. 
It is unlikely that his daughter’s symptoms are related to WFS1, and we suspect that the p.R558C 
variant likely acts in a recessive manner. 
One of the most striking aspects of the case presented here is the profound thiamine 
deficiency, and its devastating impact on the patient’s memory. The symptom complex of diabetes 
mellitus, deafness, and optic atrophy has been found in association with defects in thiamine 
metabolism previously in the context of thiamine-responsive megaloblastic anemia syndrome, or 
Rogers syndrome (OMIM # 249270)27-29. Rogers syndrome, a recessive condition caused by 
mutations in the thiamine transporter SLC19A2, is characterized by thiamine-responsive 
megaloblastic anemia, sensorineural deafness, and DM; its phenotypic similarity to Wolfram 
syndrome suggests the possibility that disruption of thiamine metabolism may contribute to the 
pathophysiology of Wolfram syndrome. The coding exons of SLC19A2 were sequenced in our 
patient and no rare mutations were detected, although the presence of non-coding variants cannot 
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be excluded. Given that there was no dietary reason for our patient to develop thiamine deficiency, 
his case suggests that WFS1 may affect thiamine transport or utilization. Furthermore, given that 
there are no therapies available for the treatment of Wolfram syndrome, assessment of thiamine 
sufficiency and possibly empiric thiamine supplementation should be considered for these patients.  
The patient presented here had a diagnostic journey that is not unusual for disorders 
involving dysfunction across multiple organ systems, in that several years elapsed and numerous 
costly genetic tests were performed without a molecular diagnosis. The application of MitoExome 
sequencing in this case illustrates how clinical application of next-generation sequencing technology 
can allow for rapid, simultaneous evaluation for multiple genetic disorders with a single test thereby 
accelerating the diagnostic process. Furthermore, this case demonstrates how careful study of an 
individual patient with a rare disorder can yield potentially new insight into gene function and 
disease pathogenesis.  
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Abstract   
Objective: To describe a patient with a previously undiagnosed neurological disorder whose 
diagnosis was informed through targeted exome sequencing with copy number variant analysis. 
Design: Case report. 
Setting: Tertiary referral center. 
Patient: 35-year-old man with cerebellar ataxia, peripheral neuropathy, hearing loss, cognitive 
impairment, and azoospermia.  
Main Outcome Measures: Clinical features, neuroimaging and metabolic findings, muscle biopsy 
with biochemical and histochemical analysis, and genetic studies. 
Results:  Commercially available genetic tests for inherited ataxias and mitochondrial disorders were 
negative. Serum, urine, and muscle biopsy findings pointed to a mitochondrial disorder while 
elevated ratios of pristanic:phytanic acid and arachidonic:docosahexaenoic acid were consistent with 
a peroxisomal disorder. Targeted exome sequencing and a computational algorithm to infer copy 
number variants revealed compound heterozygous mutations in HSD17B4, which encodes the 
peroxisomal D-bifunctional protein, including a 12kb in-frame deletion of exons 10-13 and a 
missense variant (p.A196V) within an NAD+ binding domain at a residue conserved to bacteria. 
Recessive mutations in HSD17B4 are a known cause of peroxisomal D-bifunctional protein 
deficiency (OMIM #261515) and have been reported in sisters with ataxia, hearing loss, and ovarian 
dysgenesis (Perrault syndrome; OMIM #233400).  Our patient’s phenotypic overlap with previous 
cases, severity of mutations in HSD17B4, and metabolic evidence of peroxisomal dysfunction, led to 
a diagnosis of Perrault syndrome due to HSD17B4 deficiency. 
Conclusions: This is the first reported case of a male with ataxia and infertility due to recessive 
HSD17B4 mutations, expanding the phenotype of Perrault syndrome. Our study highlights the 
importance of copy number variants in the diagnosis of neurological disorders, and points to 
potential crosstalk between mitochondria and peroxisomes in the pathogenesis of HSD17B4 
deficiency and Perrault syndrome. 
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Introduction 
atients with mitochondrial disorders frequently present with cerebellar ataxia, often together 
with other neurological and non-neurological symptoms.1 Such disorders can be caused by 
mutations in the mitochondrial DNA or by recessive, dominant, or X-linked mutations in nuclear-
encoded genes essential to mitochondrial respiratory chain function.2 Due to genetic and phenotypic 
heterogeneity, single gene testing is often ineffective and targeted sequencing approaches have been 
utilized to identify the genetic basis of disease in infantile- and adult-onset cases of suspected 
mitochondrial disease.3 Here, we performed targeted exome analysis in an adult with cerebellar 
ataxia and other neurological and non-neurological features. 
 
Patient 
A 35-year-old man presented for evaluation of a gait disorder progressing since childhood, 
cognitive impairment, and sensorineural hearing loss. He had mildly delayed developmental 
milestones, including sitting at 8 months, walking at 14 months, talking at 18 months, and difficulty 
reading at age 6. Running was impaired at age 7, and sports impossible by age 9. Progressive ataxia 
necessitated a cane by age 18, wheelchair-dependence by 29. He needed assistance academically 
through school, and graduated from college in his 30’s. Sensorineural hearing loss was noted at age 
34. Review of medical charts revealed documented azoospermia. He was the product of 
neurologically healthy, non-consanguineous parents, with one healthy, fertile sister. The patient’s 
father died of cancer in his early 60’s. 
Neurological examination revealed high arched feet, hammer toes, and normal secondary 
sexual characteristics. Oculomotor examination showed square wave jerks at rest, gaze-evoked 
nystagmus, saccadic intrusions into pursuit, hypermetric saccades, and failure to suppress the 
vestibular ocular reflex. There was mild dysarthria, moderate upper and lower extremity dysmetria, 
P 
          52 
and moderate gait ataxia (Brief Ataxia Rating Scale: 13/30). Deep tendon reflexes were normal in the 
arms, exaggerated in the legs. Plantar responses were flexor. He had impaired pin sense in the feet. 
Hearing was intact on office testing. He had an average IQ, bland affect, reduced visual motor 
processing speed, and was impaired on a card-sorting test.  
Brain MRI from age 14 through 35 showed progressive cerebellar volume loss (Figure 4.1). 
Nerve conduction studies revealed absent long latency responses in the legs, symmetrically reduced 
motor conduction velocities in arms and legs with normal amplitudes; needle examination was 
normal. Waking electroencephalogram was normal. Audiology testing revealed mild decrease in 
hearing for higher frequencies bilaterally, decreased speech intelligibility, and word recognition 86% 
on the right, and 94% on the left. 
Pertinent normal laboratory studies included thyroid functions, vitamins E and B12, copper, 
ceruloplasmin, serum protein electrophoresis, serum tissue transglutaminase and gliadin antibodies, 
RPR, ANA, and lactate. Normal genetic tests included SCA1, 2, 3, 5, 6, 7, 8, 10, 14, 17, DRPLA, 
FRDA, AOA1, 2, POLG, MELAS, MERRF and NARP. Endocrine tests with normal results were 
LH 11 mIU/mL (2-12), somatomedin 112 ng/mL (114-492), and prolactin 11 ng/mL (2-19).  
Abnormal laboratory results included low testosterone at 164 ng/dL (270-1100), increased 
FSH at 15 mIU/mL (1-8), and elevated pyruvate 0.18 (0.08-0.16). A number of serum amino acids 
were elevated, including alanine 638 (146-494), asparagine 121 (26-92), glutamic acid 75 (6-62), 
isoleucine 103 (39-90), lysine 260 (119-243), methionine 38 (13-37), proline 310 (97 – 297), and 
valine 365 (172 – 335). Elevated urine organic acids were present including small amounts of lactic, 
succinic, and 2-oxoglutaric acids. Tests of long- and very long-chain fatty acids revealed elevated 
total plasma ω-9 fatty acids. The percentage of C18:2ω6 (linoleic) was low and the ratio of pristanic 
acid / phytanic acid, percentage of arachidonic acid, and arachidonic/ docosaehexenoic acid ratio 
were elevated.  
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Figure 4.1. MRI at age 35 demonstrating cerebellar volume loss with preservation of cerebral 
hemispheres. A-D) FLAIR axial; E-H) T2 axial; I-J) Coronal T1; K-L) Sagittal T1 
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Muscle biopsy was normal on light and electron microscopy.  Muscle coenzyme Q10, free 
and total carnitine, and acylcarnitine were normal, but electron transport chain testing revealed mild 
Complex I deficiency (22% Complex I+III after normalization to citrate synthase).  
Given a classification of “probable” mitochondrial disease based on clinical, metabolic, and 
biochemical features,4 informed consent was obtained from the patient and his family to undergo 
targeted DNA sequencing for suspected mitochondrial disease.  
 
Methods 
Genotyping  
PCR of deletion (hg19 chr5:118825016-118837334del_insA; NM_000414:c.715-1207del) 
was performed using AccuPrime kit (Life Technologies) with extension time 80s and annealing 
temperature of 55 degrees Celsius. The following primers were used, as depicted in Figure 4.2E: 
GGGAATGAATGGTACCCAGAT (red), GCTTTCATTTTGAACATGGTTG (blue), 
TTTTACCATCCACAGGCTCAC (black).  
AccuPrime PCR of SNV (NM_000414:c.587C>T) was performed using an extension time 
of 1 minute and an annealing temperature of 54 degrees Celsius.  The following primers were used: 
AGTTGCTTTTGATAGGTGCAG (forward) & CCCCATTGTGTA AAACAAAAA (reverse). 
 
Multiple sequence alignment 
Multiple alignment of HSD17B4 protein in Figure 4.2A was created by aligning the 
following Uniprot IDs with ClustalW5: P51659, P51660, Q98TA2, Q9NKW1, Q9VXJ0, Q02207, 
Q9I4V1. 
 
Variant annotation 
Genetic variants were annotated with predictions from PolyPhen26, and variant frequencies 
from Exome Variant Server7 and 1000 Genomes8. 
          55 
Results 
Targeted capture of mitochondrial DNA and the exons of 1598 nuclear genes implicated in 
mitochondrial biology, mitochondrial disease, or neurological disorders with phenotypic overlap was 
performed as previously described.3 Variant calling through the Genome Analysis Toolkit identified 
1,569 single nucleotide variants (SNVs) and small insertions/deletions (indels) in the patient’s 
sample with 205x mean coverage and 95.1% of targeted bases covered at >10x. We applied filters to 
identify potentially pathogenic variants including mtDNA variants previously known to be 
pathogenic as well as rare, protein-modifying variants that were hemizygous X-linked, autosomal 
recessive, or present in dominant-acting disease genes, as previously described.3 No variants passed 
our filters and a genetic basis of disease remained unclear. 
As our previous analyses focused only on SNVs and indels, we subsequently applied 
CONIFER to identify large copy number variants (CNVs) in our targeted exome data. 9 CNV 
analysis revealed a potential 13kb heterozygous in-frame deletion of exons 10-13 of HSD17B4 
(c.715-1207del; p.239_403del) (Figure 4.2). Review of patient exome data revealed that the patient 
also harbored a rare, heterozygous missense variant in HSD17B4 (c.587C>T; p.A196V). This variant 
was not present in EVS nor 1000 Genomes, altered a residue conserved to bacteria within a 
predicted NAD-binding domain, and is predicted to be “probably damaging” by PolyPhen2. 
Familial genotyping confirmed the presence of an inherited heterozygous deletion and revealed that 
the variants were compound heterozygous in the proband: the deletion, which was heterozygous in 
the proband’s healthy sister, was likely inherited from the father, while the missense variant was 
inherited from the mother. 
Recessive mutations in HSD17B4 cause D-bifunctional protein deficiency (OMIM 
#261515), a severe disorder of peroxisomal fatty acid beta-oxidation that is generally fatal within the 
first 2 years of life, 10 and have recently been identified in two sisters diagnosed with Perrault 
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Figure 4.2. Compound heterozygous variants in HSD17B4.  
A) Schematic of HSD17B4 (NP_000405) with multiple sequence alignment. SCP2, sterol carrier 
protein 2; #, cleavage site. B) Pedigree denoting genotypes. C) Normalized depth of coverage at 
each exon (“x”); lines represent smoothed data from proband (red) and controls (black). Below, 
reads showing deletion-spanning mate pairs. D) Sanger trace of c.587C>T. E) DNA gel indicating 
genotypes at deletion site, schematic of primers, and Sanger trace across deletion in proband. 
Abbreviations: wt, wildtype; nd, no data; del, deletion, norm, normalized. 
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syndrome (OMIM #233400), who exhibited severe sensorineural deafness, ovarian dysgenesis, 
peripheral neuropathy and ataxia.11 Due to the phenotypic overlap with previous cases, the predicted 
severity of the HSD17B4 mutations, and evidence of altered peroxisomal very-long-chain fatty acid 
metabolism, we reached a diagnosis of Perrault syndrome in our patient. 
 
Discussion 
HSD17B4, also known as D-bifunctional protein (DBP), is a peroxisomal enzyme that 
catalyzes multiple steps of beta-oxidation of very long chain fatty acids (VLCFA). Although named 
for its homology to a steroid-converting enzyme, the protein’s role in steroid hormone metabolism 
is unclear. The protein consists of three domains: an N-terminal dehydrogenase domain, a hydratase 
domain, and a sterol carrier protein (SCP) domain. The three amino acids at the C-terminus 
(“AKL”) constitute the peroxosimal targeting signal (PTS). After peroxisomal import, the 79-kDa 
full-length protein is proteolytically cleaved to yield a 35-kDa dehydrogenase subunit and a 45-kDa 
hydratase subunit containing the hydratase and SCP domains. 
Recessive mutations in HSD17B4 are known to cause DBP-deficiency, an early-onset 
neurological disorder characterized by neonatal hypotonia, seizures, visual impairment, and 
psychomotor retardation.10 Patients with the disorder generally die in infancy, although a small 
number survive into their teens. Like our patient, individuals with DBP deficiency often show an 
elevated ratio of pristanic to phytanic acid in plasma, reflective of dysfunctional beta-oxidation in the 
peroxisome.12   
DBP-deficiency has been classified into subtypes based on the affected enzymatic activities 
of HSD17B4. Type I patients have deficiencies of both the hydratase and dehydrogenase subunits 
whereas types II and III have isolated hydratase or dehydrogenase deficiency, respectively. Recently, 
a Type IV category was proposed to describe mildly affected patients with compound heterozygous 
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mutations affecting both subunits.13 Our case may be classified as type IV due to the mutations 
affecting both subunits and the phenotypic similarity between our patient and two teenage brothers 
categorized as type IV, including the presence of cerebellar ataxia, polyneuropathy, pes cavus, and 
hearing loss.13 
In addition to causing DBP-deficiency, recessive mutations in HSD17B4 have been 
identified in two sisters diagnosed with Perrault syndrome (OMIM #233400). Perrault syndrome 
was first defined in 1951 as ovarian dysgenesis and sensorineural hearing loss in females.14 Brothers 
of Perrault syndrome females have been reported with hearing loss but typically are fertile.15 While 
autosomal recessive inheritance has been observed, the syndrome is genetically heterogeneous.16 
Recessive mutations in three additional genes have been implicated in Perrault syndrome: HARS2, 
LARS2, and CLPP, that respectively encode the mitochondrial histidyl-tRNA synthetase, leucyl-
tRNA synthetase, and a mitochondrial ATP-dependent protease.17-19 
The phenotype and genotype of our patient resemble those of the two Perrault syndrome 
sisters.11  Both families presented with infertility, cerebellar ataxia, demyelinating polyneuropathy, 
pes cavus, and hearing loss. Both had compound heterozygous HSD17B4 variants consisting of a 
missense mutation predicted to affect NAD-binding in the dehydrogenase domain and a predicted 
loss-of-function mutation in the hydratase subunit. Our patient had azoospermia rather than 
complete gonadal dysgenesis, and it is noteworthy that HSD17B4 knockout mice, which accumulate 
VLCFA but show no neurological abnormalities, exhibit male-specific sterility with testicular lipid 
accumulation.20  
While HSD17B4 is listed in the MitoCarta inventory due to its strong co-expression and 
homology with bona fide mitochondrial proteins and its proteomic identification in mitochondrial 
isolates,21 prior experimental studies have physically localized the protein to the peroxisome.22 It is 
known that abnormal peroxisomal fatty acid catabolism can lead to secondary mitochondrial 
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dysfunction.23 This case, together with prior examples of disease caused by dual-localized 
mitochondrial/peroxisomal proteins (e.g., AMACR), raises the hypothesis that defects within the 
peroxisome can lead to secondary defects within mitochondria. 
The discovery of a multi-exon deletion compounded with a rare missense mutation suggests 
that CNV detection may be a crucial addition to standard exome analysis. Our patient represents the 
first male patient with infertility and ataxia due to recessive HSD17B4 mutations, and the second 
unrelated case with hearing loss and infertility due to recessive HSD17B4 mutations.11, 16 
Identification of additional patients with Perrault syndrome due to HSD17B4 deficiency should 
further expand the phenotypic spectrum of the disorder. 
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Abstract 
Complex II, also known as succinate dehydrogenase (SDH), is central to mitochondrial energy 
metabolism, with roles in both the mitochondrial respiratory chain and the Krebs cycle. In humans, 
mutations in Complex II subunits and assembly factors can cause hereditary tumor syndromes, such 
as paraganglioma and pheochromocytoma, as well as disorders of energy metabolism, such as 
Leigh’s disease and infantile leukoencephalopathy. We have developed a computational approach 
utilizing the information inherent in bacterial operons to predict novel components of 
mitochondrial pathways and protein complexes. This method has implicated the uncharacterized 
mitochondrial protein C6orf57 and its yeast homologue, FMP21, in a role in Complex II activity. 
Studies of isolated biochemical activity in FMP21 deletion strains reveal compromised Complex II 
and Complex II+III activity. Sequencing of germline DNA from 72 patients with 
pheochromocytoma or paraganglioma of unknown genetic etiology revealed no rare coding variants 
in C6orf57. Future work hopes to elucidate the specific role of the protein in Complex II biology 
and to confirm the finding in mammalian systems. This study suggests that C6orf57 may be a novel 
assembly factor for Complex II and is a candidate gene for future studies of paraganglioma and 
pheochromocytoma. 
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Introduction 
uccinate dehydrogenase (SDH), also known as Complex II of the mitochondrial respiratory 
chain, is the only enzyme complex involved in both oxidative phosphorylation and the Krebs 
cycle, making it a central component of mitochondrial energy metabolism. SDH catalyzes the 
oxidation of succinate to fumarate and couples the reaction to the reduction of ubiquinone. There 
are four core subunits of Complex II (SDHA, SDHB, SDHC, SDHD), which are encoded in the 
nuclear genome in mammals and in the yeast Saccharomyces cerevisiae. SDHA, a flavoprotein, and 
SDHB, and iron-sulfur protein, form the catalytic subunits while SDHC and SDHD represent 
membrane anchor subunits. In yeast, the homologues of SDHA-D are SDH1-4, respectively. 
In mammals, two complex II assembly factors have been identified: SDHAF1, also known 
as SDH6/YDR379C-A in yeast, which has been implicated in infantile leukoencephalopathy 1, and 
SDHAF2, also known as SDH5/EMI5 in yeast, 2 that has been linked to paraganglioma. SDH5 is 
required for flavination of SDHA, 3 while SDH6 is thought to affect the insertion or retention of 
iron-sulfur clusters within Complex II. 1 The yeast protein TCM62, which has homology to the 
mitochondrial chaperonin HSP60 in humans, has also been identified as a complex II assembly 
factor 4, although it is unclear to what extent the protein’s role is specific to Complex II assembly. 
Succinate dehydrogenase deficiency can result in a number of human diseases. Mutations in 
SDHA can cause Leigh syndrome 5 and mutations in SDHAF1 can cause infantile 
leukoencephalopathy 1. In addition, germline mutations in SDHB, SDHC, SDHD, and SDHAF2 
can lead to rare neuroendocrine tumor conditions, accounting for 20-40% of patients with 
paraganglioma or pheochromocytoma. 6 While our understanding of the genetic basis for these 
tumors has improved dramatically over the last decade, no likely deleterious germline mutations in 
known susceptibility genes are identified in 30-60% of cases of paraganglioma/pheochromocytoma, 
suggesting that causal genetic loci remain to be discovered. 6 
S 
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The evolutionary relationship between mitochondria and bacteria enables computational 
inference of mitochondrial gene function through analysis of bacterial gene neighborhoods. It is 
believed that mitochondria are derived from a bacterial ancestor whose close symbiosis with its 
eukaryotic host eventually led to the complete integration of the two organisms 7. Over the course of 
evolution, many of the genes encoded by the mitochondrial genome were transferred to the 
eukaryotic host genome such that today only 13 of the 1,500 estimated human mitochondrial 
proteins are encoded by the mitochondrial DNA. The remainder of the mitochondrial proteome is 
encoded in the nuclear genome and 60% of mammalian mitochondrial proteins have close bacterial 
homologues, enabling researchers to study protein function using strategies developed for bacteria 8.  
Bacterial genomes are organized into operons, which are functional units of genomic DNA 
containing a cluster of genes under the control of a single regulatory signal or promoter. Often, 
operons contain multiple genes involved in a particular metabolic pathway or protein complex. For 
example, all thirteen subunits of Complex I, also known as NADH dehydrogenase or 
NADH:ubiquinone oxidoreductase, are encoded by the nuo operon in E. coli. 9 The phenomenon of 
spatial clustering of functionally related genes has enabled the inference of bacterial gene function, 
an approach referred to as operon analysis or inference by genomic context. 10, 11 Currently, there are 
over 700 sequenced bacterial genomes freely available through NCBI for which the genes have been 
assigned to operons 12. The wealth of operon data provides a resourceful way to discover 
relationships among bacterial proteins, and by extension, amongst eukaryotic proteins with close 
bacterial homologues. 
To identify novel components of Complex II, and therefore potential paraganglioma 
candidate genes, we have developed a computational approach utilizing the extensive homology 
between mitochondrial and bacterial proteomes as well as the information inherent in bacterial 
operons.  
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Methods 
Operon analysis 
Sequences for 675 prokaryotic species (Bacteria and Archaea) were downloaded from 
KEGG in May 2009. Protein sequences for 1098 mouse mitochondrial proteins were obtained from 
http://www.broadinstitute.org/pubs/MitoCarta/.8 BlastP with 1e-3 e-value cutoff was used to find 
homology between MitoCarta and prokaryotic proteomes.13 Prokaryotic operon predictions were 
downloaded from DOOR 12. For each pair of MitoCarta proteins, we counted the number of genera 
(based on species name) that (a) contained homologues of both genes predicted to be in the same 
operon or (b) contained homologues of both genes in the genome. Each pair of genes received an 
Op/Cop score defined as (a)/(b). For each pair of genes, we then calculated the Pearson correlation 
over the Op/Cop scores across all genes. This matrix was then hierarchically clustered with Matlab 
(clusterdata) using default parameters. 
 
Yeast Co-expression 
FMP21 was selected as input to SPELL version 2.03 (http://spell.princeton.edu/), which 
was used with default settings and a maximum of 100 results. 14 
 
Phylogenetic profiling 
121 eukaryotic proteomes, 68 archaeal, and 942 bacterial proteomes were downloaded from 
NCBI. PFAM domains were predicted by PfamScan 15 using default parameters. For each species, 
the number of proteins with a domain was counted.  The Pearson correlation of these scores across 
all bacterial species was determined between each PFAM protein domain and DUF1674 (PF07896). 
 
Respiratory phenotype in yeast 
Data for the respiratory phenotype of the yeast deletion collection was downloaded from 
(http://www-deletion.stanford.edu/YDPM/Download_Data/Yeast_Deletion_Project/Regression_Tc2_hom.txt). 16 
          65 
For each deletion strain, the Pearson correlation across all growth conditions was calculated relative 
to the fmp21 (YBR269C) deletion. 
 
Biochemical assays in yeast 
Isolated Complex II (DCPIP reduction) and II+III (cytochrome c reduction) assays were 
performed as previously described. 17 Citrate synthase was measured using the citrate synthase assay 
kit (Sigma CS0720). Protein quantitation was performed with the BCA assay kit (Thermo Scientific 
Pierce 23225). 
 
Strain creation and media conditions 
Wildtype strains and haploid yeast knockout strains of fmp21 (YBR269C), sdh2(YLL041C) 
and emi5/sdh5 (YOL071W) were obtained from yeast knockout collection (courtesy of C. Kiely and 
F. Winston). Wildtype background strain is BY4741 (his3Δ1, leu2Δ0, met15Δ0, ura3Δ0). Gene 
deletion was confirmed through colony PCR using primers “TTTCAAAGATATATTTTCAGCGAGG” 
and “AAAAGCACTAGAAAGACTGTCTCCA”. 18 Strains were grown in YPD media unless otherwise 
specified. Mitochondrial isolation was performed as previously described. 19 
FMP21 was amplified by PCR from WT yeast using primers 
“GGGGACAAGTTTGTACAAAAAAGCAGGCTCCACCAAAAATGTTGTGCGCCATCAAAAGC” and 
“GGGGACCACTTTGTACAAGAAAGCTGGGTCGAAATCCGTTACTCTTCCGTTAAAC” and cloned into 
pYES-DEST52 plasmid (Life Technologies) under a GAL1 promoter. Plasmid containing FMP21 
or empty plasmid was transformed using one-step transformation of yeast. 20 Yeast colonies 
transformed with the plasmid were selected and tested in SC-URA media containing 20% galactose.  
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Germline sequencing of tumor syndrome patients 
Germline DNA from 72 patients with pheochromocytoma or paraganglioma and clinical or 
transcriptional features consistent with pseudohypoxic-type tumors was tested for mutations in all 
three exons of C6orf57 including 3’ and 5’ UTR. Informed consent was obtained according to a 
University of Texas Health Science Center at San Antonio (UTHSCSA) Institutional Review Board 
(IRB)-approved protocol. All patients had previously tested negative for mutations in SDHB, 
SDHC, SDHD, VHL, RET, NF1 and TMEM127. Most cases were also negative for mutations in 
SDHAF2/SDH5, but they have not been checked for SDHA mutations. Sequencing was performed 
at Beckman Genomics and analyzed using the Mutation Surveyor Software (Softgenetics).  
The following PCR primers were used to amplify C6orf57 exons and UTRs: 1F, 
CCAGGGATGCCTCTAACTCC; 1R, GGGAGGCGCTTCTCTCTG; 2F, TTTCACTCTGCGTCCTTTTG; 2R, 
TCTTTCCTTTCACTCATTTTCTCA; 3F, CTGGGCAACAGAGGGAGA; 3R, GCAGCATATTTTCTTCCAAAGC; 
3UTR-F, TTCTTTCTTTATATCCTTTATGTCGTG; 3UTR-R, CCTCCTGGGTTTAAGCCATT. 
 
Results 
Gene neighborhoods for bacterial homologues of C6orf57 
We used protein homology along with predictions of bacterial operons across 675 
prokaryotic genomes to determine the pairs of mitochondrial proteins whose bacterial homologues 
consistently share gene neighborhoods across multiple unrelated species. Clustering this data 
revealed modules of mitochondrial protein homologues that tended to co-locate within bacterial 
operons. Manual inspection of these clusters revealed coherent clusters of proteins involved in 
diverse complexes and pathways including respiratory chain Complexes I, II, III/IV, and V, 
mitochondrial ribosome, Fe-S cluster biogenesis, fatty acid metabolism, ABC transporters, Krebs 
cycle, and glycine cleavage. 
We manually inspected each cluster in order to determine whether there were any novel 
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candidate genes not known to associate with other members of the cluster. Only the Complex II 
cluster contained a gene of unknown function with operon evidence linking it to the majority of 
genes within the cluster. In addition to the known SDH subunits with strong bacterial homology 
(SDHA, SDHB, and SDHC), this cluster contained C6orf57, a completely uncharacterized protein. 
A closer look at the bacterial homologues of C6orf57 revealed that the protein is found in a 
conserved operon in a number of bacterial species along with all four subunits of Complex II 
(Figure 5.1). Among all bacterial proteins, the closest bacterial homologue of human C6orf57 is 
xccb100_2045 of Xanthomonas campestris, a gammaproteobacteria. This gene lies in an operon 
conserved across at least twelve species of gammaproteobacteria and one species of 
betaproteobacteria. Interestingly, this operon and nearly all of the homologous operons also contain 
the recently identified Complex II assembly factor SDH5 (also known as SDHAF2 in humans, and 
SDHE in bacteria), which has been shown to play a role in the flavination of SDHA. 2, 3  
While the closest bacterial homologue to C6orf57 lies in an operon with Complex II 
subunits and an assembly factor, there are other bacterial homologues whose gene neighborhoods 
may shed light into the role and function of C6orf57. In multiple species of alphaproteobacteria 
including Rickettsia prowazekii, the species considered to be the closest relative of the mitochondrial 
ancestor, a DUF1674 domain protein (RP167 in R. prowazekii) lies adjacent to a protein containing a 
polyketide cyclase domain (PF03364), which is involved in polyketide synthesis or the binding & 
transport of lipids. Interestingly, these polyketide cyclase domain-containing proteins are 
homologous to human proteins COQ10A and COQ10B and to yeast COQ10. In yeast, COQ10 is a 
ubiquinone-binding protein thought to function in the delivery of Q6 to its proper location in the 
mitochondrial inner membrane. 9 21 The observation that C6orf57 homologues lie in operons with 
homologues of Complex II subunits and ubiquinone transport factors lie suggests that perhaps 
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Figure 5.1. Conserved operon encoding homologues of C6orf57 , SDHA-D , and SDHAF2 .  
Bacterial gene identifiers are listed below their homologues in human. Arrows represent 
transcriptional directionality of bacterial operons. Most of these operons also encode a homologue 
of the recently identified Complex II assembly factor SDHAF2 (also known as SDH5). All bacterial 
species represent gamma-proteobacteria except for Pusillimonas sp T7-7, which is beta-
proteobacterial. Species are sorted in order of decreasing homology between human C6orf57 and 
the bacterial DUF1674 homologue. Dashes represent the absence of a homologue in the operon. 
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DUF1674 proteins are involved in the interplay between Complex II and ubiquinone, which is 
needed to transfer electrons from Complex II to Complex III. 
 
Localization of C6orf57 
C6orf57 is amongst the strongest predictions of being mitochondrial localized according to 
MitoCarta 8. The protein is predicted by TargetP and MitoPred to have a mitochondrial localization 
signal, has a mitochondrial homologue in yeast (FMP21), has a homologue in Rickettsia prowazakeii 
(RP167), is strongly co-expressed with other mitochondrial proteins (11/50 nearest neighbors in co-
expression space are known mitochondrial proteins), and is found in mitochondrial fractions by 
MS/MS in three mouse tissues: adipose, small intestine, & testis. The Human Protein Atlas 
(http://www.proteinatlas.org/) has experimentally shown mitochondrial localization of the protein 
across multiple cell types. 17 Altogether, there is strong computational and experimental evidence 
that the protein is localized to the mitochondrion. 
 
Structure and conservation of C6orf57 protein 
In humans, the C6orf57 protein is 108 amino acids and consists of an N-terminal 
mitochondrial targeting sequence (amino acids 1-22) and a C-terminal DUF1674 domain at aa 40-
108 (Figure 5.2A). DUF1674 (PF07896) is a domain of unknown function approximately 60 amino 
acids in length that is found in many eukaryotic and bacterial organisms.  The domain is found at the 
C-terminus across nearly all species with the domain. There are a number of conserved residues near 
the C-terminus (Figure 5.2B), including a stretch of conserved residues forming the motif 
“GPEPTRY” and the terminal two amino acids, “DF”. A range of 3D structures was determined 
experimentally for a bacterial homologue of C6orf57, Rhr2 in the alphaproteobacteria Rhodobacter 
sphaeroides (PDB 2K5K). While some models show the protein in a toric conformation, a number of 
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other conformations suggest a high degree of structural flexibility (Figure 5.2C). While the global 
conformation varies widely between the different 3D models of the protein, the local conformations 
consistently suggest the presence of a kinked or helical C-terminal tail.  
 
Presence of DUF1674 in Evolution 
Evolutionarily, the DUF1674 (PF07896) domain is present in a number of alpha-, beta-, and 
gamma-proteobacteria, as well as in some protists and most eukaryotes. The domain is almost 
always C-terminal (426/427 species in PFAM database) and the proteins are typically small (typically 
<100 amino acids in bacteria, <200 in eukaryotes). The domain is present in >87% of 121 
eukaryotic species sequenced to date, with notable exceptions including some microsporidian and 
diatom species. The protein is present in at least two species of protists (Phytophthora ramorum, 
Phytophthora sojae), 88 alpha-proteobacterial genomes (75% of 117), 1 beta-proteobacterial species 
(Pusillimonas sp. T7-7), and 12 gamma-proteobacterial genomes (5% of 238). 
Phylogenetic profiling across bacterial genomes reveals that the presence of DUF1674 in a 
genome is correlated with the presence, in that genome, of a number of other PFAM domains, 
including HIG_1_N (PF04588), DUF1982 (PF09326), NDUFA12 (PF05071), ATP12 (PF07542), 
ETC_C1_NDUFA4 (PF04800), NADH5_C (PF06455), and CybS (PF05328). Many of these 
represent core structural domains of known respiratory complex or super-complex assembly factors, 
including HIG2A and ATPAF2. 18, 22 Interestingly, CybS, which is the primary domain in human 
SDHD, is not found in most bacterial species, which instead have an SDHD subunit containing the 
Sdh_cyt domain (PF01127). Given the other evidence of association between DUF1674 and 
Complex II subunits, this observation raises the hypothesis that DUF1674 may be functionally 
related to CybS-containing forms of SDHD. 
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Figure 5.2. Structure of DUF1674-containing proteins.  
A) Schematic of human C6orf57 protein showing N-terminal mitochondrial targeting 
sequence (MTS) and C-terminal DUF1674 domain. B) Multiple sequence alignment of C6orf57 
homologues in select species, highlighting residues of high homology. Uniprot IDs: Q5VUM1, 
Q8BTE0, Q6ZM06, A5G2G6, Q8P8V1, Q2RNC3, Q0A907, Q54Y25, P38345. C) Four models of 
3D structure of Rhr2 in the alphaproteobacteria Rhodobacter sphaeroides (PDB 2K5K). N-terminus to 
C-terminus is colored blue to red, with DUF1674 at the C-terminus.
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FMP21: respiratory phenotype and co-expression in yeast 
Many species of fungi possess homologues of C6orf57, including the budding yeast S. 
cerevisiae in which the homologue is FMP21 (YBR269C). This protein has been localized to the 
mitochondrion through proteomic analyses 20 and has 41% identity to the human protein across the 
DUF1674 domain. Other than being identified in a screen as one of 84 genes required for 
protection from hyperoxia toxicity, 12 the function and role of FMP21 is unknown. 
Multiple large-scale studies have shown that deletion of FMP21 results in a respiratory 
phenotype. 16, 23 Interestingly, a reanalysis of the Steinmetz et al. data shows that the respiratory 
phenotype of this gene is remarkably similar to that of other Complex II subunits, in that these 
deletion strains showed a severe growth deficiency when grown in glycerol or lactate as the carbon 
source media but a milder phenotype when grown in ethanol. Analysis of the respiratory phenotype 
across nine media conditions reveals that the fifteen genes whose knockout respiratory profile is 
most correlated with FMP21’s include all five Complex II-related proteins for which there is data 
(SDH5, SDH4, TCM62, SDH1 and SDH2; no data for SDH3 and YDR379C-A). While this list of 
genes also includes a number of other proteins involved in the Krebs cycle (FUM1, CIT1), there is a 
strong enrichment for Complex II-related genes (p<1e-15). 
There is also co-expression evidence linking FMP21 to components and assembly factors of 
Complex II. According to SPELL (Hibbs et al., 2007), five out of the seven known Complex II 
subunits/assembly factors are found within the top 150 genes co-expressed with FMP21: SDH4 
(#7), SDH2 (#34), EMI5/SDH5 (#41), SDH3 (#99), and SDH1 (#146). Co-expression of FMP21 
(YBR269C) and SDH4 (YDR178W) has also been observed previously through automated 
clustering algorithms. 24  
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Complex II activity of FMP21 deletion 
The operon, co-expression, and respiratory phenotype analyses support the hypothesis that 
C6orf57 and its yeast homologue, FMP21, play a role in Complex II biology. To test this hypothesis 
experimentally, we obtained FMP21 knockouts and measured Complex II activity, comparing the 
activity to that of wildtype strains or deletion strains for Complex II subunits and assembly factors. 
Deletion of FMP21 in a haploid strain resulted in approximately two-fold reduction in Complex II 
and Complex II+III activity (Figure 5.3A). While the two-fold reduction is statistically significant, 
knockouts of sdh2 and emi5 showed a ten-fold decrease in residual activity in both Complex II+III 
and Complex II activity compared to wildtype. We expressed a plasmid with FMP21 under a GAL1 
promoter in the fmp21 deletion strain and rescued Complex II+III activity to 90% of wildtype 
(Figure 5.3B), demonstrating that the reduction in Complex II+III activity is due to the absence of 
FMP21. Complex II activity has not yet been tested in this rescue system. Our results demonstrate 
that deletion of FMP21 significantly impairs Complex II activity, but to a lesser extent than deletion 
of Complex II subunits or assembly factors. 
 
Sequencing patients with paraganglioma and pheochromocytoma 
Given the computational and experimental evidence of C6orf57’s involvement in Complex 
II activity, and the role of Complex II subunits and assembly factors in rare neuroendocrine tumors, 
we sequenced the exons of C6orf57 in germline DNA from 72 patients with paraganglioma or 
pheochromocytoma of unknown etiology. While several known polymorphisms were detected in 
C6orf57, including rs1048886 and rs13654, no rare coding mutations were detected in the patients. 
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Figure 5.3. Complex II activity in yeast knockouts.  
Complex II or Complex II+III activity was measured in whole cell lysate and normalized to protein 
content (BCA assay). This was plotted as percent of wildtype (wt) activity. Error bars represent 
standard error (two technical replicates). A) Complex II or II+III activity assay in yeast knockout 
strains B) Complex II+III assay in yeast knockouts or knockout + rescue grown in SC-URA media 
+10% galactose.  
 
20%
40% 
60% 
80% 
100% 
120% 
20%
40% 
60% 
80% 
100% 
120% 
wt fmp21 sdh2 emi5 
Re
la
tiv
e 
ac
tiv
ity
 (%
 w
t) 
Re
la
tiv
e 
ac
tiv
ity
 (%
 w
t) 
Complex II or II+III activity in yeast knockouts Complex II+III activity in fmp21 rescue
CII / BCA 
CII+III / BCA 
wt fmp21 fmp21  +
GAL1-FMP21
sdh2
CII+III / BCA 
A B
          75 
Discussion 
Through a computational screen utilizing bacterial operons, we identified a potential 
functional relationship between the uncharacterized protein C6orf57 and Complex II of the 
mitochondrial respiratory chain, also known as succinate dehydrogenase. The operon of the closest 
bacterial homologue of C6orf57 contains all four subunits of Complex II and the homologue of 
SDHAF2, a recently identified Complex II assembly factor. This operon is conserved across 13 
proteobacterial species. 
Experimental and computational evidence involving FMP21, the C6orf57 homologue in 
yeast, support the hypothesis that C6orf57 is involved in Complex II function. FMP21 is highly co-
expressed with four out of five SDH subunits or assembly factors and the deletion strain shows a 
two-fold reduction in Complex II+III activity, which can be rescued by expression of the gene from 
a plasmid, and a two-fold reduction in Complex II activity. The experimental evidence suggests that 
FMP21 is required for maximal Complex II and II+III activity but does not result in as severe a 
Complex II phenotype as would SDH2 or SDH5 deletion strains, since such strains reduced 
Complex II activity to 10% residual activity. Such a result is reminiscent of Chen et al., in which 
Rcf1 is described as a protein not essential for basal mitochondrial function but essential for 
optimally efficient ETC function and respiration. 22 In fact, phylogenetic profiling shows that the 
HIG1 domain of Rcf1 and the DUF1674 domain of FMP21 are highly correlated across bacteria 
(r=0.81). 
Whereas SDHAF2 was found to catalyze the flavination of SDHA, there is evidence 
suggesting that C6orf57’s role may be related to the interface between Complex II and ubiquinone. 
First, FMP21 is closely co-expressed with SDH4, both relative to all proteins as well as to among 
Complex II subunits and assembly factors. Second, DUF1674 has a correlated phylogenetic profile 
across bacteria with the CybS domain of SDHD. Third, the DUF1674 protein of Rickettsia prowazekii 
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lies adjacent to a homologue of COQ10, which is involved in ubiquinone binding and transport. 
These observations raise the hypothesis that C6orf57 impacts the mitochondrial inner membrane, 
possibly by affecting the interaction between SDHD and ubiquinone. 
Germline mutations in SDHB, SDHC, SDHD, and SDHAF2 can cause increased risk of 
paraganglioma and pheochromocytoma (PGL/PCC) and we therefore hypothesized that C6orf57 
may represent a novel candidate. However, sequencing the exons of C6orf57 in 72 PGL samples did 
not uncover any rare, non-synonymous mutations. Our result suggests that germline C6orf57 
mutations are not a common cause of PGL/PCC. It should be noted, however, that only a single 
pathogenic variant in SDHAF2 has been identified to date, and this variant has only been reported 
in two PGL families, despite sequencing of over 300 individuals.2,25 This implies that mutations in 
PGL/PCC genes can be quite rare, requiring germline DNA from hundreds of patients before 
uncovering mutations in a particular susceptibility gene. In addition to sequencing germline DNA 
from more individuals, somatic DNA should also be analyzed for mutations in C6orf57. 
If C6orf57 does not play a role in tumorigenesis, it is possible that it plays a role in other 
disease contexts. Recessive mutations in SDHA and SDHAF1 can cause mitochondrial respiratory 
chain disorders including Leigh syndrome and infantile leukodystrophy, and C6orf57 is similarly a 
candidate for such severe disorders. In mice, the homologue of C6orf57 (1110058L19Rik) has been 
implicated in innate immunity, as RNAi knockdown of the gene blocks the production of IL-6 in 
J774A.1 macrophages. 26 In humans, the SNP rs1048886 (C6orf57: p.Q46R) was found to be 
associated with risk of type 2 diabetes in in South Asians at genome-wide significance. 27 28 However, 
this result has not been replicated and furthermore, rs1048886 is in linkage disequilibrium with 
variants in neighboring gene FAM135A, making it unclear which of the two genes is implicated in 
the association.  
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In conclusion, we have identified a putative role for C6orf57 in Complex II of the 
mitochondrial respiratory chain. In yeast, deletion of its homologue, FMP21, results in a two-fold 
decrease in Complex II activity. However, it is possible that FMP21 and C6orf57 may affect the 
function of multiple respiratory chain complexes and this should be investigated further. Future 
work should seek to further characterize the FMP21 deletion strain and to determine whether the 
protein can bind lipids in vitro. In addition, the role of C6orf57 should be studied in mammalian 
systems using RNAi knockdown and knockout mice. Finally, germline and somatic DNA from 
PGL/PCC patients should be sequenced at this locus to determine whether mutations in C6orf57 
may play a role in tumorigenesis. 
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CHAPTER VI: 
Implications and Future Directions 
 
hrough the development of MitoExome sequencing and its application to multiple sets of 
patients with suspected or confirmed mitochondrial disease, we have gained insight into the 
genetic architecture of the disease and into the benefits and limitations of next-generation 
sequencing for the molecular diagnosis of mitochondrial disorders. 
 
The efficacy of next-generation sequencing approaches in mitochondrial disease 
 Most rare disease sequencing studies report only the successes – i.e., individuals or patient 
cohorts in which sequencing successfully informed the genetic basis of disease. As a result, the 
efficacy of next-generation sequencing-based approaches at identifying the genetic basis of disease 
remains an open question. 
The diagnostic efficacy of next-generation sequencing will likely differ among diseases and 
our laboratory has focused on patients with suspected mitochondrial disorders. We have analyzed 
two distinct sets of patients in the course of our research. Prior to the work described in this 
dissertation, our laboratory sequenced and analyzed DNA from a set of 42 severe infantile cases 
with strong biochemical evidence of mitochondrial disease. 1 As described in Chapter II-IV, we also 
T 
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sequenced a diverse set of 102 patients referred to Massachusetts General Hospital (MGH) with 
suspicion of a mitochondrial disorder based on clinical and biochemical criteria. For the set of 42 
severe infantile patients, we found that MitoExome sequencing enabled molecular diagnoses in 26% 
of cases lacking a prior molecular diagnosis, with an additional 29% harboring strong recessive 
candidate genes, including three genes that have been independently validated or confirmed as 
disease genes since our publication (EARS2, NDUFB3, AGK).  
The diagnostic efficacy for the set of diverse MGH patients was much lower than in the 
infantile set, however, with only seven new molecular diagnoses amongst 84 patients without prior 
molecular diagnoses (8%). Although 26 additional patients harbored variants of unknown 
significance, including 10 patients with recessive mutations in mitochondrial localized proteins or in 
genes associated with monogenic disorders, it is unclear whether any of these mutations are causal. 
Our study demonstrates that clinical sequencing currently yields new molecular diagnoses that may 
not have been achieved through traditional genetic testing methods, however the diagnostic efficacy 
is far from perfect, currently around 10-30% for mitochondrial disorders. Our results demonstrate 
that the diagnostic efficacy of sequencing is highly dependent on the set of patients tested, i.e. the 
denominator in the fraction of molecular diagnoses achieved. Not surprisingly, sequencing-based 
diagnostic approaches are more likely to be effective in patients with early-onset disease and strong 
biochemical evidence of an enzymatic or metabolic deficiency. Our results inform the expectations 
surrounding exome sequencing and its ability to reveal new molecular diagnoses for patients with 
suspected genetic disorders. 
An important question to consider is why there is a difference in the diagnostic efficacy 
between the severe infantile and diverse MGH patient sets. While there is no clear answer, there are 
a number of possible explanations. The first is that the diverse MGH cases likely contain a larger 
fraction of non-mitochondrial diseases, due to the selection criteria of strong biochemical evidence 
          82 
of mitochondrial dysfunction in the infantile cohort. While we sequenced 200 genes encoding non-
mitochondrial proteins known to be associated with monogenic neurological or metabolic disorders 
-- and in fact found several causal mutations in these genes -- there are hundreds of other Mendelian 
disease genes that were not sequenced. Furthermore, it could be that a larger number of MGH 
patients harbored causal mutations in non-mitochondrial proteins not yet known to cause disease, 
although such mutations will be admittedly hard to identify as pathogenic given the large number of 
non-mitochondrial proteins relative to our sample size. If feasible, whole-exome sequencing should 
be performed on the patients who currently lack a molecular diagnosis in order to determine 
whether such an approach would increase the diagnostic yield. Another possibility is that while 
severe infantile cases are caused by rare, protein-modifying, highly conserved variants, less severe 
cases may be caused by mutations that are less rare, less conserved, or may have subtler effects on 
gene function (e.g., regulatory variants). Such variants may not be fully penetrant. Finding such 
causal variants will be more challenging and will require many more patients than analyzed at 
present, due to the higher background frequency of such variants in healthy individuals. 
 
Non-mitochondrial proteins implicated in mitochondrial disease 
One of the most striking aspects of our work was the repeated discovery of causal genetic 
defects that would not classically be considered causes of mitochondrial disorders. Of the seven 
genes implicated in new molecular diagnoses (ATP5A1, POLG2, NDUFV1, DPYD, KARS, WFS1, 
and HSD17B4), only three encode proteins that are uniquely localized to the mitochondria 
(ATP5A1, POLG2, and NDUFV1). The others are either dual-localized (KARS), or are currently 
believed to localize outside the mitochondria (DPYD, WFS1, HSD17B4). KARS is dual-localized to 
the cytoplasm and mitochondria, DPYD localizes to the cytoplasm, WFS1 localizes to the 
endoplasmic reticulum (ER), and HSD17B4 localizes to the peroxisome. Previous studies have also 
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identified mutations in non-mitochondrial proteins associated with mitochondrial dysfunction. Two 
siblings with refractory epilepsy and mitochondrial dysfunction were recognized through exome 
sequencing to have homozygous nonsense mutations in GM3 synthase (ST3GAL5), a lysosomal 
protein. 2 Multiple patients with MEGDEL syndrome (3-methylglutaconic aciduria with 
sensorineural deafness, encephalopathy, and Leigh-like syndrome) were found to carry recessive 
loss-of-function mutations in SERAC1, which localizes to the mitochondrial-ER interface. 3 Our 
study and others demonstrate that secondary mitochondrial dysfunction may be more common than 
previously thought. 
Our study suggests that patients with suspected mitochondrial disorders may frequently 
harbor causal genetic defects in non-mitochondrial proteins. Given current technological capabilities 
and their marginal costs, it is likely worthwhile to sequence all previously established Mendelian 
disease genes in these patients, rather than just those genes canonically associated with 
mitochondrial disorders. In order to keep up with the continually expanding list of previously 
established disease genes, it may even be worthwhile for clinical testing laboratories to sequence the 
patient’s whole-exome but to limit the analysis to known disease genes. It is important for both 
physicians and patients to understand that a patient with clinical, biochemical, or metabolic features 
suggestive of mitochondrial disease may turn out not to have a primary genetic lesion in a 
mitochondrial protein. The percentage of suspected mitochondrial disease caused by primary versus 
secondary mitochondrial dysfunction is currently unknown. Knowing this information could have 
broad implications for the diagnosis and treatment of suspected mitochondrial disorders. 
 
Future directions 
The insights gained through our work have raised as many questions as they have answered. 
Further study is needed to pursue many of these findings.  
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The contribution of non-mitochondrial genes to mitochondrial dysfunction 
A promising area of mitochondrial disease research is to determine the ways by which 
organellar crosstalk may lead to mitochondrial dysfunction. As whole-exome sequencing studies are 
performed on patients with suspected mitochondrial disorders, we expect an increase in the number 
of non-mitochondrial proteins implicated in these disorders. For the non-mitochondrial proteins 
implicated in this study (DPYD, HSD17B4, and WFS1), clinical and experimental studies are needed 
to uncover whether and how their disruption leads to mitochondrial dysfunction. A systematic study 
of the biochemical, metabolic, mtDNA, and histologic measurement of mitochondrial function in 
Wolfram syndrome, DPD deficiency, and HSD17B4-deficiency would be informative. For example, 
it would be worthwhile to study the effect of HSD17B4 knockdown on mitochondrial function and 
determine whether alterations in fatty acid supplementation may alter mitochondrial function or cell 
viability.  
 
Genetic and phenotypic data aggregation 
Both for mitochondrial disease patients and for patients suspected of other genetic 
disorders, a key next step is to build platforms enabling shared discoveries among physicians and 
scientists across the world. Dozens of patients whose genomes have been analyzed by our laboratory 
have harbored potentially deleterious genetic variants that, due to their rarity, have never before 
been seen before by our laboratory. However, it is likely that another patient with a similar 
phenotype and genotype will be found somewhere in the world at some point in the future. There is 
a need to build a platform that is able to connect the researchers or clinicians observing these 
patients, and even to connect the patients themselves. A simple solution is the creation of a 
platform, perhaps one similar to the site www.craigslist.org, whereby clinicians and researchers can 
post a short summary of the clinical presentation and the genetic findings, and then could be 
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contacted by others who are interested in the genetic or phenotypic findings. Such an approach 
would safeguard the anonymity of the information and could greatly increase the flow of 
information across the globe. An alternative to this approach, which would be more involved but 
also more powerful, would be to build a shared repository of datasets that can be queried by the 
research community. Such a platform would greatly accelerate the pace of genetic research and could 
have a large impact on our understanding of human disease. 
 
Automated phenotype-genotype correlation 
Another computational task would be to create an algorithm that could, in an automated 
fashion, interpret the patient’s genetic information in the context of their clinical information. The 
algorithm would predict the likelihood of a variant or variant set of contributing to disease given a 
particular clinical phenotype. Much of my PhD was spent manually poring over genetic and 
phenotypic data of patients and determining whether there was sufficient genotype-phenotype 
correlation to merit a molecular diagnosis. For example, two of our patients had recessive mutations 
in WFS1, however only one had symptoms consistent with Wolfram syndrome. Another example 
would be our patient who harbored recessive HSD17B4 mutations and, though the patient was 
male, shared many phenotypic traits with a pair of sisters previously diagnosed with Perrault 
syndrome due to HSD17B4-deficiency. 
 
Experimental systems for variant interpretation 
Although a number of computational algorithms exist to predict whether a variant may 
deleterious to protein function, there has been relatively little work done in setting up experimental 
systems to quantify the impact of a variant. The Duke Center for Human Disease Modeling has 
shown a number of successful applications of using a zebrafish model to test variants in a wide 
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variety of genes affecting development, 4, 5 yet this approach is limited to mostly developmental 
phenotypes and can be quite laborious. One idea is to use cellular models such as the yeast S. 
cerevisiae, the amoeba Dictyostelium discoideum, or even mammalian tissue culture models to model 
cellular phenotypes at a larger scale. For example, given a strong, quantifiable respiratory phenotype 
upon deletion of the yeast homologue of POLG, one could imagine rescuing the deletion strain with 
every POLG allele observed in humans in order to assess variant impact. One could even test 
potentially dominant-acting variants by expressing POLG variants in a wildtype strain, rather than in 
the deletion, and assessing variant impact. In yeast, there are over 600 mitochondrial proteins with 
homology to human, of which 200 are known to be associated with a respiratory phenotype. This 
system could thus be generalized to much of the mitochondrial proteome.  
 
Conclusion 
While our understanding of genetics and its relationship to human disease is still limited, it is 
my hope that the experimental and computational approaches described in this dissertation provide 
a foundation for future methodologies and discoveries. As the price of sequencing continues to drop 
and as computational and experimental tools are developed to pinpoint the variants most likely to 
cause disease, the pace of research is likely to accelerate greatly. Within the next few years, we are 
likely to uncover the vast majority of genes underlying monogenic diseases and may start to uncover 
more complex patterns of genetic inheritance. There has never been a more exciting time to 
participate in biomedical research and I look forward to the discoveries of the coming years. 
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APPENDIX A 
 
Supplementary Materials for Chapter II:  
Targeted exome sequencing of suspected mitochondrial disorders 
 
Appendix A-1: Supplementary Methods 
MitoExome sequencing 
Targeted gene transcripts from the RefSeq1 and UCSC known gene2 collections were downloaded 
from the UCSC genome browser3 assembly hg19 (February 2009) corresponding to all genes listed 
in Table A-1. Single 120bp baits were synthesized on a chip (Agilent) for each target region, or tiled 
across targets that exceeded 120bp. Two Agilent bait sets were synthesized: design1 contained 
42,119 baits targeted to mtDNA and 1,560 nuclear genes (coding regions and 5’ UTRs, single bait 
per target), and design2 contained 25,963 baits targeted to mtDNA and a superset of 1,598 nuclear 
genes (coding regions only, two baits per nuclear target and single bait per mtDNA target). Genomic 
DNA was sheared, ligated to Illumina sequencing adapters, and selected for lengths between 200-
350bp. This “pond” of DNA was hybridized with an excess of Agilent baits in solution. The “catch” 
was pulled down by magnetic beads coated with streptavidin, then eluted.4, 5 Index tags were added 
to 60 samples to facilitate “barcoded” multiplex sequencing. All samples were sequenced at the 
MGH Next-Generation Sequencing Core (http://nextgen.mgh.harvard.edu). 42 samples were 
sequenced in singleplex (one sample per lane, Agilent bait design1) and 60 barcoded samples were 
multiplexed (4-12 samples per lane, Agilent bait design2).  
 
Variant detection 
Sequence alignment, variant detection, and variant annotation for the nuclear and mitochondrial 
genomes were performed as described previously,6 with modifications described here. Illumina reads 
were aligned to the GRCh37 reference human genome assembly using BWA7 and variants were 
detected and annotated using the Genome Analysis Toolkit (GATK) software package version 
1.0.5973 8 and custom scripts. The ReadBackedPhasing algorithm was used to determine the phase 
of heterozygous variants. For the analysis of mtDNA, all reads were separately aligned to the 
mtDNA revised Cambridge Reference Sequence (NC_012920) and heteroplasmy level for SNVs 
was estimated based on the GATK pooled variant caller (Unified Genotyper v1.0.2986) assuming a 
mixture of 500 mtDNA chromosomes (-poolSize 500). mtDNA indels were detected using the 
standard Unified Genotyper and heteroplasmy was estimated as the percentage of aligned reads 
containing the variant. mtDNA variants supported by ≥1% of aligned reads were detected. Variants 
present at <20% heteroplasmy were deemed tentative until confirmed at higher heteroplasmy in an 
independent DNA sample or a maternal relative. We developed an algorithm to exclude mtDNA 
variants derived from sequence artifacts or nuclear sequences of mitochondrial origin (NuMTs)9, 
based on filtering out low-heteroplasmy variants (<10%) that met the following criteria: (i) were 
present in at least 10% of samples, (ii) showed apparent paternal transmission based on sequencing 
of five trios, or (iii) exhibited correlation with the nuclear:mitochondrial DNA content across the 
102 patients (p<0.01 Bonferroni-corrected, t-test of Spearman correlation). The 
nuclear:mitochondrial DNA ratio was estimated by the ratio of reads aligning to chromosome 1 to 
reads aligning to mtDNA, respectively. Large mtDNA deletions or rearrangements were detected 
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through de novo mtDNA assembly using a modified ALLPATHS assembly approach, as previously 
described.6  
 
Confirmatory genotyping and phasing 
All variants underlying molecular diagnoses were independently validated by Sanger sequencing, and 
compound heterozygous variants were phased through read-backed phasing (GATK version 
1.0.5973), sequencing familial DNA, or haplotype inference using genotype data from 1000 
Genomes. For haplotype inference, two rare variants in the same gene observed together in multiple 
individuals were considered unlikely to be compound heterozygous and thus excluded, whereas two 
rare variants in the same gene observed to be mutually exclusive across multiple individuals were 
considered to be likely compound heterozygous. 
Heteroplasmy levels for three known pathogenic mtDNA mutations (MELAS, MERRF, NARP) 
were quantified at in DNA derived from whole blood and/or patient lymphoblastoid cell lines 
(LBLs) using ARMS quantitative PCR (Medical Genetics Laboratories, Baylor College of Medicine, 
Test ID 3006).10 Dihydropyrimidine dehydrogenase (DPD) deficiency was confirmed by a purine 
and pyrimidine panel (Mayo Clinic, Test ID 81420).  
 
Modeling the ATP5A1 p.Y321C mutation in yeast  
An atp1 null mutant was created in the W303-1A S. cerevisiae yeast strain (a, ade2-1, his3-1, 15, leu2–3, 
112, trp1-1, ura3-1) by homologous recombination of PCR products using the KanMX resistance 
marker, as previously described.11 pRS305 plasmids expressing the wildtype or p.Y315C allele of 
ATP1 were created via Quikchange (Agilent). Residue numbering is based on the precursor peptide. 
Multiple sequence alignment was performed using ClustalW2 
(http://www.ebi.ac.uk/Tools/msa/clustalw2) with the following UniProt IDs: P25705, Q03265, 
P35381, P07251, and P0ABB0. 
 
dbGaP accessions 
Patient identifiers from this study are listed in dbGaP phs000339 with the prefix “MGO”. 
 
Appendix A-2: Supplementary Notes 
MitoExome sensitivity and specificity 
For each individual, we detected SNVs and indels compared to the reference human genome. On 
average, individuals had 24 homoplasmic mtDNA variants, 1470 nuclear SNVs, and 56 nuclear 
indels. Over 95% of nuclear SNVs in each individual represented common polymorphisms in 
existing databases. 
To assess sensitivity and specificity, we performed MitoExome sequencing on two HapMap 
individuals (NA12878, NA12891) with publicly available genotype data (HapMap Phase 3 release 2) 
and deep-coverage whole-genome data (1000 Genomes Project pilot 112). Nuclear SNVs were 
estimated to be 97.9% sensitive and 99.9% specific, based on 797 and 1655 sites genotyped using 
independent technology. We detected 78/82 (95%) of indels ranging between 1 and 13bp in size in 
our HapMap samples, based on comparisons using the same GATK indel detection algorithm on 
deep-coverage whole genome sequence data, although we note that this algorithm may have a 
significant false negative rate. Reproducibility was assessed by independent hybrid selection and 
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sequencing of HapMap sample NA12878, and showed 98% genotype concordance at heterozygous 
sites, consistent with our reported sensitivity. 
The particularly deep coverage of the mtDNA enabled us to detect mtDNA variants with both high 
and extremely low (≥1%) levels of heteroplasmy. mtDNA SNV detection was estimated at 98% 
sensitivity and 99.5% specificity, based on reports for 29 individuals with independent whole-
mtDNA sequence data (Medical Genetics Laboratories, Baylor College of Medicine, Test ID 3055). 
Additionally, we detected 11/12 sites independently assessed by quantitative PCR (qPCR) from the 
same tissue sample, including 5/6 variants present at <10% heteroplasmy (Table A-4). At one site 
(m.3243A>G) assessed across seven individuals with MELAS, we observed strong correlation 
(R2=0.98) between the levels of heteroplasmy in LBLs as estimated by NGS read count versus qPCR 
(Figure A-6 panel A). However, the estimates of heteroplasmy consistently differed by two-fold 
between these two methods. We note that qPCR validation was performed at only three mtDNA 
sites and that other study designs, such as sequencing pre-defined mixtures of mtDNA species,13 are 
required to reliably assess the accuracy of NGS-based quantitation of heteroplasmy. 
Heteroplasmy in LBL versus whole blood 
Previous studies have shown that the levels of heteroplasmy depend on the source of the DNA.14 
Comparison of m.3243A>G heteroplasmy levels by qPCR in LBL versus whole blood revealed 
consistently higher heteroplasmy levels in whole blood (Figure A-6 panel B). This emphasizes the 
importance of tissue selection in future NGS studies of mitochondrial disease.  
 
Loss-of-function variants in LBLs from MELAS patients 
We observed that lymphoblastoid cell lines derived from MELAS patients carrying the m.3243A>G 
mutation harbored a large number of low-heteroplasmy loss-of-function (LOF) variants (i.e. 
frameshift indels and nonsense mutations). Specifically, we observed a tenfold enrichment of LOF 
mutations: 5 such mutations in samples from 7 MELAS patients (Table A-4) versus 8 in all 102 
patients (p<1e-3, binomial exact test). No enrichment was observed for missense or synonymous 
variants. The five LOF mutations in MELAS patients included four in complex I subunit and two 
that were previously reported as somatic mutations (m.5260G>A and m.4788G>A).15, 16 
Interestingly, somatic LOF mutations in Complex I subunits, including the m.5260G>A mutation, 
have been previously associated with oncocytic thyroid tumors.17 Further studies are required to 
evaluate whether the m.3243A>G MELAS mutation causes a preferential accumulation of somatic 
loss-of-function mtDNA mutations either in vivo or in cell culture.  
 
Prioritized variants of unknown significance (pVUS) in mtDNA 
Six patients harbored pVUS in mtDNA that did not meet the requirements for molecular diagnosis, 
as described here:  
• Patients 1008 and 1038 harbored pVUS in RNR1 (m.1555A>G, m.1494C>T) that were not 
consistent with the previously reported phenotype of aminoglycoside-induced hearing loss. 
18, 19 
• Patient 1011 harbored two heteroplasmic pVUS (COX1:p.G140X 42% heteroplasmy, 
COX2:p.W106X, 16% heteroplasmy) that were Sanger-confirmed in DNA from LBLs but 
were not detected in an independent blood sample from the patient or from an affected 
daughter, likely representing cell-line mutations. 
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• Patients 1051, 1085, and 1014 harbored low-heteroplasmy variants that have not yet been 
confirmed in an independent DNA sample (Table A-5). These include two mutations 
previously reported in patients with MELAS 20, 21 and a COX2 nonsense mutation also 
detected in Patient 1011.  
 
Prioritized variants of unknown significance (pVUS) in nuclear disease genes 
11 patients harbored pVUS in established nuclear disease loci that did not meet the requirements for 
molecular diagnosis, as summarized here: 
• Eight patients harbored pVUS that were not consistent with previously reported phenotypes 
of the relevant genes. Five of these patients harbored rare recessive variants in established 
autosomal recessive disease genes (DNAI1, DPYD, ETFB, SECISBP2, WFS1), and four 
patients harbored rare heterozygous variants in dominant-acting disease genes (POLG, 
POLG2).  
• Three patients harbored X-linked pVUS that did not have enough support to warrant 
diagnosis: 
o A hemizygous missense AIFM1:p.G53A variant was detected in male patient 1104. 
The variant was not present in the Exome Variant Server (EVS) nor 1000 Genomes. 
Previously, a hemizygous frameshift mutation in AIFM1 was identified in a male 
with severe encephalopathy.22 More recently, a hemizygous p.G308E missense 
mutation was identified in a patient with early prenatal ventriculomegaly and 
postnatal developmental delay.23 The patient phenotype was not similar enough to 
either previous report to warrant molecular diagnosis. 
o A hemizygous HCCS:p.A174V variant located near a splice site was detected in male 
patient 1002. The variant was present in 0/2443 male and 1/4060 female X 
chromosomes in EVS. Previous reports indicate that deletions, nonsense mutations, 
and de novo missense mutations in HCCS can cause male-lethality and X-linked 
dominant microphthalmia in females (OMIM #309801).24 25, 26 The patient 
phenotype was not similar enough to previous reports to warrant molecular 
diagnosis 
o A heterozygous NDUFA1:p.G32R variant was detected in female patient 1100 with 
complex I deficiency (22% normalized complex I+III activity). The variant was 
found to be hemizygous in an affected brother and DNA from a second affected 
brother was unavailable. This mutation has previously been reported in the 
heterozygous state in a single female with complex I deficiency and in the 
hemizygous state in multiple males with complex I deficiency.27, 28 However this allele 
is present at 1% allele frequency (AF) in European Americans in the Exome Variant 
Server and therefore may represent a polymorphism.  
 
Recessive KARS mutations 
Patient 1098 harbored compound heterozygous missense mutations in KARS (Figure A-2), which 
were phased through parental genotyping. The p.T587M variant was absent from dbSNP, 1000 
Genomes, and Exome Variant Server (EVS)29 and altered a residue conserved to E. coli. The 
p.P228L variant was positioned within the anti-codon binding domain and altered a residue 
conserved to C. elegans, similar to the p.L133H mutation previously shown to impair aminoacylation 
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in vitro.30  The p.P228L variant was present in 2/12994 chromosomes in EVS. Both patient 
mutations were predicted to be “probably damaging” by PolyPhen2.31  
Recessive KARS mutations have been associated with peripheral neuropathy (OMIM #613641) 
based on a single patient with peripheral neuropathy, developmental delay, dysmorphic features, and 
vestibular Schwannoma.30  Patient 1098, who died by age 4, had no reports of peripheral neuropathy 
and no EMG or nerve conduction studies were performed to our knowledge. In addition to the 
single published case, compound heterozygous KARS mutations were recently identified in two 
siblings who presented in infancy with microcephaly, cortical blindness, developmental delay, and 
seizures (Abstract #701F, 62nd Annual Meeting of the American Society of Human Genetics).32 We 
hypothesize that peripheral neuropathy could be a later-onset feature of recessive KARS mutations, 
just as recessive mutations in DARS2 have been associated with childhood- or adolescent-onset 
peripheral neuropathy in addition to early-onset neurological symptoms such as tremors and 
ataxia.33, 34 Further investigation of patients with recessive KARS mutations will likely expand the 
phenotypic spectrum associated with this disorder. 
 
Hypothesized mechanism of ATP5A1 mutation causing combined respiratory chain deficiency  
How might a mutation in the complex V subunit ATP5A1 lead to combined respiratory chain 
deficiency and mtDNA depletion? Yeast experiments have shown that nearby mutations in this 
protein lead to loss of membrane potential and to mtDNA instability.11 We hypothesize that human 
ATP5A1 mutations may act in a similar manner. The mutation may cause uncoupling of complex V, 
which could lead to decreased membrane potential and subsequent loss of mtDNA by an undefined 
mechanism. The mtDNA loss would lead to decreased synthesis of mtDNA-encoded respiratory 
chain subunits and thus deficiencies of multiple respiratory chain complexes, as observed in the 
patient and her affected sister. Future experiments in mammalian cells are needed to explore this 
hypothesis.
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Table A-1. Nuclear gene products targeted in this study 
AADAT 
AAK1 
AARS 
AARS2 
AARSD1 
AASS 
ABAT 
ABCA1 
ABCA9 
ABCB1 
ABCB6 
ABCB7 
ABCB8 
ABCB9 
ABCB10 
ABCC12 
ABCD1 
ABCD2 
ABCD3 
ABCD4 
ABCE1 
ABCF2 
ABHD5 
ABHD10 
ABHD11 
ABO 
ACAA1 
ACAA2 
ACACA 
ACACB 
ACAD8 
ACAD9 
ACAD10 
ACAD11 
ACADL 
ACADM 
ACADS 
ACADSB 
ACADVL 
ACAT1 
ACAT2 
ACBD3 
ACLY 
ACN9 
ACO1 
ACO2 
ACOT1 
ACOT2 
ACOT4 
ACOT7 
ACOT8 
ACOT9 
ACOT11 
ACOT12 
ACOT13 
ACOX1 
ACOX3 
ACP6 
ACSF2 
ACSF3 
ACSL1 
ACSL3 
ACSL4 
ACSL5 
ACSL6 
ACSM1 
ACSM2A 
ACSM3 
ACSM4 
ACSM5 
ACSS1 
ACSS3 
ACY1 
ACYP2 
ADAMTSL2 
ADCK1 
ADCK2 
ADCK4 
ADCK5 
ADH1C 
ADH5 
ADHFE1 
ADO 
ADSL 
AFG3L1 
AFG3L2 
AGA 
AGK 
AGL 
AGMAT 
AGPAT5 
AGPS 
AGR2 
AGXT 
AGXT2 
AGXT2L2 
AHSA1 
AIFM1 
AIFM2 
AIFM3 
AK1 
AK2 
AK3 
AK3L1 
AKAP1 
AKAP10 
AKR1B10 
AKR1B15 
AKR1C1 
AKR1D1 
AKR7A2 
ALAD 
ALAS1 
ALAS2 
ALDH1A3 
ALDH1B1 
ALDH1L1 
ALDH1L2 
ALDH2 
ALDH3A1 
ALDH3A2 
ALDH3B1 
ALDH4A1 
ALDH5A1 
ALDH6A1 
ALDH7A1 
ALDH9A1 
ALDH18A1 
ALDOA 
ALDOB 
ALKBH7 
ALPL 
AMACR 
AMN 
AMT 
ANGEL2 
ANKRD13C 
ANKRD16 
ANKRD26 
AOX1 
APBB1 
APEX2 
APOA1BP 
APOOL 
APTX 
ARAF 
ARG1 
ARG2 
ARHGAP17 
ARMC1 
ARMC4 
ARMC10 
ARMS2 
ARSA 
ARSB 
ARX 
AS3MT 
ASAH1 
ASAH2 
ASL 
ASMTL 
ASS1 
ATAD1 
ATAD3A 
ATAD3B 
ATCAY 
ATG5 
ATIC 
ATM 
ATN1 
ATP1A1 
ATP5A1 
ATP5B 
ATP5C1 
ATP5D 
ATP5E 
ATP5F1 
ATP5G1 
ATP5G2 
ATP5G3 
ATP5H 
ATP5I 
ATP5J 
ATP5J2 
ATP5L 
ATP5O 
ATP5S 
ATP5SL 
ATP7B 
ATP10D 
ATPAF1 
ATPAF2 
ATPIF1 
ATXN1 
ATXN2 
ATXN3 
ATXN7 
ATXN10 
AUH 
AURKAIP1 
B4GALT5 
BAD 
BAK1 
BAX 
BBOX1 
BCAT1 
BCAT2 
BCKDHA 
BCKDHB 
BCKDK 
BCL2 
BCL2L1 
BCL2L2 
BCL2L13 
BCS1L 
BDH1 
BDH2 
BEAN 
BID 
BLOC1S1 
BLOC1S3 
BNIP3 
BNIP3L 
BOLA1 
BPHL 
BRCA1 
BRP44 
BRP44L 
BSG 
BZRAP1 
C1orf31 
C1orf69 
C1orf93 
C1orf151 
C1orf172 
C1orf212 
C1orf222 
C1QBP 
C2orf47 
C2orf56 
C2orf64 
C3orf1 
C3orf23 
C3orf31 
C4orf14 
C4orf48 
C5orf33 
C6orf57 
C6orf72 
C6orf81 
C6orf125 
C6orf136 
C6orf203 
C7orf10 
C7orf55 
C8orf38 
C8orf55 
C8orf82 
C9orf46 
C9orf89 
C9orf98 
C9orf123 
C10orf2 
C10orf10 
C10orf58 
C11orf48 
C12orf10 
C12orf62 
C12orf65 
C14orf2 
C14orf68 
C14orf153 
C14orf156 
C14orf159 
C15orf48 
C15orf61 
C17orf42 
C17orf61 
C17orf89 
C17orf90 
C18orf19 
C18orf55 
C19orf47 
C19orf70 
C20orf7 
C20orf24 
C20orf72 
C21orf33 
C21orf57 
C22orf32 
CA5A 
CA5B 
CABC1 
CACNA1A 
CAD 
CANX 
CARKD 
CARS2 
CASP8 
CASQ1 
CBARA1 
CBR4 
CBS 
CCBL1 
CCBL2 
CCDC51 
CCDC56 
CCDC58 
CCDC90A 
CCDC90B 
CCDC109A 
CCDC109B 
CCDC136 
CCS 
CCT2 
CCT5 
CCT7 
CD36 
CDKL5 
CDKN2A 
CDS2 
CECR5 
CEND1 
CERK 
CHAT 
CHCHD1 
CHCHD2 
CHCHD3 
CHCHD4 
CHCHD6 
CHCHD7 
CHCHD10 
CHDH 
CIDEA 
CISD1 
CKMT1A 
CKMT1B 
CKMT2 
CLIC4 
CLN3 
CLPB 
CLPP 
CLPX 
CLYBL 
CMA1 
CMC1 
CMPK1 
COL2A1 
COMT 
COMTD1 
COPS3 
COPS4 
COPS5 
COPS6 
COQ2 
COQ3 
COQ4 
COQ5 
COQ6 
COQ7 
COQ9 
COQ10A 
COQ10B 
COX4I1 
COX4I2 
COX4NB 
COX5A 
COX5B 
COX6A1 
COX6A2 
COX6B1 
COX6B2 
COX6C 
COX7A1 
COX7A2 
COX7A2L 
COX7B 
COX7C 
COX8A 
COX8C 
COX10 
COX11 
COX15 
COX16 
COX17 
COX18 
COX19 
CPOX 
CPS1 
CPT1A 
CPT1B 
CPT1C 
CPT2 
CRAT 
CRLS1 
CROT 
CRY1 
CS 
CSF2RB 
CTH 
CTNS 
CTPS2 
CTSA 
CTSB 
CTU1 
CUBN 
CXorf23 
CYB5B 
CYB5R1 
CYB5R2 
CYB5R3 
CYC1 
CYCS 
CYP7B1 
CYP11A1 
CYP11B1 
CYP11B2 
CYP17A1 
CYP24A1 
CYP27A1 
CYP27B1 
D2HGDH 
DACT2 
DAP3 
DARS 
DARS2 
DBH 
DBI 
DBT 
DCAF5 
DCAKD 
DCI 
DCXR 
DDAH1 
DDC 
DDT 
DDX28 
DECR1 
DECR2 
DELXQ28 
DGUOK 
DHCR24 
DHDPSL 
DHODH 
DHRS1 
DHRS4 
DHRS11 
DHTKD1 
DHX29 
DIABLO 
DIS3 
DLAT 
DLD 
DLST 
DMGDH 
DNAI1 
DNAJA3 
DNAJC4 
DNAJC11 
DNAJC15 
DNAJC19 
DNAJC27 
DNAJC30 
DNLZ 
DNM1L 
DPY30 
DPYD 
DPYS 
DRD4 
DRG2 
DTNBP1 
DUS2L 
DUSP16 
DUSP26 
DUT 
DYM 
EARS2 
EBP 
ECH1 
ECHDC3 
ECHS1 
ECM1 
ECSIT 
EDF1 
EEFSEC 
EFHA1 
EFHD1 
EHHADH 
EIF2B1 
EIF2B2 
EIF2B3 
EIF2B4 
EIF2B5 
EIF3I 
EIF3K 
ELAC2 
ELN 
ENDOG 
ENO3 
EPRS 
ESR1 
ESR2 
ETFA 
ETFB 
ETFDH 
ETHE1 
EXOG 
FABP1 
FABP3 
FAHD1 
FAHD2A 
FAHD2B 
FAM36A 
FAM38A 
FAM65C 
FAM81A 
FAM82A1 
FAM82A2 
FAM82B 
FAM134B 
FAM136A 
FAM162A 
FAM167B 
FAM195A 
FARS2 
FASN 
FASTK 
FASTKD1 
FASTKD2 
FBXO18 
FBXO34 
FDPS 
FDX1 
FDX1L 
FDXR 
FECH 
FGF14 
FGF20 
FH 
FIBP 
FIS1 
FITM2 
FKBP8 
FLJ35220 
FLJ40434 
FMO3 
FMR1 
FOXRED1 
FPGS 
FRMD3 
FTCD 
FTH1 
FTMT 
FTSJ2 
FUCA1 
FUNDC2 
FXC1 
FXN 
FXYD2 
G6PC 
GAA 
GAD1 
GADD45GIP1 
GALC 
GALNS 
GAMT 
GARS 
GART 
GATC 
GATM 
GBA 
GBAS 
GBE1 
GCAT 
GCDH 
GCK 
GCSH 
GFER 
GFM1 
GFM2 
GGPS1 
GGT1 
GHITM 
GHR 
GIMAP5 
GK 
GK2 
GLA 
GLB1 
GLDC 
GLOD4 
GLRX 
GLRX2 
GLRX3 
GLRX5 
GLS 
GLS2 
GLUD1 
GLUD2 
GLYAT 
GLYATL1 
GLYATL2 
GLYCTK 
GMPPB 
GNE 
GNG5 
GNMT 
GNPAT 
GNPTAB 
GNS 
GOT1 
GOT2 
GPAM 
GPD1 
GPD1L 
GPD2 
GPHN 
GPI 
GPR56 
GPRC5C 
GPT 
GPT2 
GPX1 
GPX4 
GRHPR 
GRN 
GRPEL1 
GRPEL2 
GRSF1 
GSR 
GSS 
GSTA3 
GSTK1 
GSTO1 
GSTZ1 
GTF2H5 
GTPBP3 
GTPBP5 
GTPBP8 
GTPBP10 
GUCY2D 
GUF1 
GUSB 
GYS1 
GYS2 
H6PD 
HADH 
HADHA 
HADHB 
HAGH 
HAL 
HAMP 
HAO1 
HAO2 
HARS 
HARS2 
HAX1 
HBXIP 
HCCS 
HCLS1 
HDDC2 
HDHD3 
HEBP1 
HEMK1 
HEXA 
HEXB 
HFE2 
HGD 
HGSNAT 
HIBADH 
HIBCH 
HIGD1A 
HIGD2A 
HINT1 
HINT2 
HINT3 
HK1 
HK2 
HK3 
HLCS 
HMGCL 
HMGCLL1 
HMGCS2 
HP 
HPD 
HPDL 
HPR 
HPRT1 
HPS1 
HPS3 
HPS4 
HPS5 
HPS6 
HRSP12 
HSCB 
HSD3B1 
HSD3B2 
HSD3B7 
HSD11B1 
HSD17B3 
HSD17B4 
HSD17B8 
HSD17B10 
HSD17B14 
HSDL1 
HSDL2 
HSPA9 
HSPA13 
HSPB7 
HSPD1 
HSPE1 
HTATIP2 
HTRA2 
HYAL1 
IARS 
IARS2 
ICT1 
ID2 
IDE 
IDH1 
IDH2 
IDH3A 
IDH3B 
IDH3G 
IDI1 
IDUA 
IMMP1L 
IMMP2L 
IMMT 
INPP5B 
IQCE 
IREB2 
ISCA1 
ISCA1L 
ISCA2 
ISCU 
ISOC2 
ITM2B 
ITPR1 
IVD 
IYD 
KARS 
KCNA1 
KCNC3 
KCNJ10 
KIAA0141 
KIAA0174 
KIAA0564 
KIAA0664 
KIF1B 
KMO 
KRT5 
KRT8 
KRT18 
KYNU 
L2HGDH 
LACE1 
LACTB 
LACTB2 
LAMP2 
LAP3 
LARS2 
LCAT 
LCN2 
LCT 
LDHA 
LDHAL6B 
LDHB 
LDHC 
LDHD 
LETM1 
LETMD1 
LGSN 
LIAS 
LIFR 
LIPT1 
LIPT2 
LMBRD1 
LOC153328 
LONP1 
LONP2 
LPCAT1 
LRPPRC 
LSM7 
LYPLA1 
LYRM1 
LYRM2 
LYRM4 
LYRM5 
LYRM7 
 
MAN2B1 
MANBA 
MAOA 
MAOB 
MAP1D 
MAP3K5 
MAPK9 
MAPT 
MARCH5 
MARS 
MARS2 
MAT1A 
MAT2B 
MAVS 
MCART1 
MCAT 
MCCC1 
MCCC2 
MCEE 
MCL1 
MCOLN1 
MDH1 
MDH2 
ME1 
ME2 
ME3 
MECP2 
MECR 
METT11D1 
METTL5 
MFN1 
MFN2 
MFSD8 
MGST1 
MGST3 
MIPEP 
MLYCD 
MMAA 
MMAB 
MMACHC 
MMADHC 
MOBP 
MOCS1 
MOCS2 
MOSC1 
MOSC2 
MPG 
MPST 
MPV17 
MPV17L 
MPV17L2 
MRE11A 
MRM1 
MRP63 
MRPL1 
MRPL2 
MRPL3 
MRPL4 
MRPL9 
MRPL10 
MRPL11 
MRPL12 
MRPL13 
MRPL14 
MRPL15 
MRPL16 
MRPL17 
MRPL18 
MRPL19 
MRPL20 
MRPL21 
MRPL22 
MRPL23 
MRPL24 
MRPL27 
MRPL28 
MRPL30 
MRPL32 
MRPL33 
MRPL34 
MRPL35 
MRPL36 
MRPL37 
MRPL38 
MRPL39 
MRPL40 
MRPL41 
MRPL42 
MRPL43 
MRPL44 
MRPL45 
MRPL46 
MRPL47 
MRPL48 
MRPL49 
MRPL50 
MRPL51 
MRPL52 
MRPL53 
MRPL54 
MRPL55 
MRPS2 
MRPS5 
MRPS6 
MRPS7 
MRPS9 
MRPS10 
MRPS11 
MRPS12 
MRPS14 
MRPS15 
MRPS16 
MRPS17 
MRPS18A 
MRPS18B 
MRPS18C 
MRPS21 
MRPS22 
MRPS23 
MRPS24 
MRPS25 
MRPS26 
MRPS27 
MRPS28 
MRPS30 
MRPS31 
MRPS33 
MRPS34 
MRPS35 
MRPS36 
MRRF 
MRS2 
MSRA 
MSRB2 
MSRB3 
MTCH1 
MTCH2 
MTCP1 
MTERF 
MTERFD1 
MTERFD3 
MTFMT 
MTFR1 
MTG1 
MTHFD1 
MTHFD1L 
MTHFD2 
MTHFD2L 
MTHFR 
MTHFS 
MTIF2 
MTIF3 
MTO1 
MTP18 
MTPAP 
MTRF1 
MTRF1L 
MTRR 
MTX1 
MTX2 
MTX3 
MUC5B 
MUL1 
MUT 
MUTYH 
MVK 
MYCBP 
MYL10 
MYO5A 
NADK 
NAGA 
NAGLU 
NAGS 
NANOS1 
NAPEPLD 
NARS 
NARS2 
NBN 
NCOA4 
NCOA7 
NDN 
NDUFA1 
NDUFA2 
NDUFA3 
NDUFA4 
NDUFA4L2 
NDUFA5 
NDUFA6 
NDUFA7 
NDUFA8 
NDUFA9 
NDUFA10 
NDUFA11 
NDUFA12 
NDUFA13 
NDUFAB1 
NDUFAF1 
NDUFAF2 
NDUFAF3 
NDUFAF4 
NDUFB1 
NDUFB2 
NDUFB3 
NDUFB4 
NDUFB5 
NDUFB6 
NDUFB7 
NDUFB8 
NDUFB9 
NDUFB10 
NDUFB11 
NDUFC1 
NDUFC2 
NDUFS1 
NDUFS2 
NDUFS3 
NDUFS4 
NDUFS5 
NDUFS6 
NDUFS7 
NDUFS8 
NDUFV1 
NDUFV2 
NDUFV3 
NEDD8 
NELL1 
NEU1 
NEU4 
NFS1 
NFU1 
NFXL1 
NIF3L1 
NIPSNAP1 
NIPSNAP3A 
NIPSNAP3B 
NIT1 
NKIRAS1 
NLN 
NLRX1 
NME1 
NME1-NME2 
NME2 
NME3 
NME4 
NME6 
NMT1 
NNT 
NOP10 
NPC1 
NPC2 
NPEPPS 
NPHS2 
NPIPL3 
NPL 
NR0B1 
NR4A2 
NRD1 
NRXN1 
NSDHL 
NT5C 
NT5C3 
NT5DC2 
NT5DC3 
NT5M 
NTHL1 
NUBPL 
NUDT1 
NUDT2 
NUDT8 
NUDT13 
NUDT19 
OAS1 
OAS2 
OAT 
OCIAD1 
OCRL 
OGDH 
OGDHL 
OGFOD2 
OGG1 
OLA1 
OMA1 
OMP 
OPA1 
OPA3 
OSBPL1A 
OSGEPL1 
OTC 
OXA1L 
OXCT1 
OXCT2 
OXNAD1 
OXR1 
OXSM 
PACRG 
PAH 
PAK7 
PAM16 
PANK2 
PARK7 
PARL 
PARS2 
PAX6 
PC 
PCBD2 
PCCA 
PCCB 
PCK1 
PCK2 
PDE12 
PDF 
PDHA1 
PDHA2 
PDHB 
PDHX 
PDK1 
PDK2 
PDK3 
PDK4 
PDLIM2 
PDP1 
PDP2 
PDPR 
PDSS1 
PDSS2 
PDZK1 
PEBP1 
PECI 
PECR 
PEPD 
PET112L 
PEX1 
PEX3 
PEX5 
PEX6 
PEX7 
PEX10 
PEX11B 
PEX12 
PEX13 
PEX14 
PEX16 
PEX19 
PEX26 
PFAS 
PFKM 
PGAM2 
PGM1 
PGS1 
PHB 
PHB2 
PHGDH 
PHKA1 
PHKA2 
PHKB 
PHKG2 
PHOSPHO1 
PHPT1 
PHYH 
PHYHIPL 
PIGY 
PINK1 
PIPOX 
PISD 
PITRM1 
PLA2G1B 
PLA2G2A 
PLA2G15 
PLEKHG4 
PLIN5 
PM20D1 
PMAIP1 
PMM2 
PMPCA 
PMPCB 
PNKD 
PNP 
PNPLA8 
PNPT1 
POLDIP2 
POLG 
POLG2 
POLM 
POLQ 
POLR2F 
POLR2G 
POLRMT 
POP5 
POR 
PPA2 
PPARGC1A 
PPDPF 
PPIF 
PPM1B 
PPM1J 
PPM1K 
PPOX 
PPP1CC 
PPP2R2B 
PPT1 
PPTC7 
PRDX1 
PRDX2 
PRDX3 
PRDX4 
PRDX5 
PRDX6 
PRELID1 
PRELID2 
PREPL 
PRICKLE4 
PRKAG2 
PRKAR2B 
PRKCA 
PRKCG 
PRNP 
PRODH 
PRODH2 
PROSC 
PRPS1 
PRR5L 
PRSS35 
PSAP 
PSMA1 
PSMA2 
PSMA5 
PSMA6 
PSMA7 
PSMB1 
PSMB4 
PSMB5 
PSMB6 
PSMB7 
PSMC1 
PSMC2 
PSMC3 
PSMD4 
PSMD6 
PSMG1 
PSTK 
PTCD1 
PTCD2 
PTCD3 
PTEN 
PTGES2 
PTGR2 
PTPMT1 
PTRH1 
PTRH2 
PTS 
PUS1 
PXMP2 
PXMP3 
PYCR1 
PYGM 
QDPR 
QRSL1 
RAB1A 
RAB1B 
RAB2B 
RAB3B 
RAB3C 
RAB3D 
RAB4B 
RAB8B 
RAB11A 
RAB11B 
RAB11FIP5 
RAB18 
RAB22A 
RAB24 
RAB31 
RAB32 
RAB35 
RAB39B 
RABL3 
RABL4 
RAF1 
RARS 
RARS2 
RBM16 
RDH13 
RDH14 
REEP1 
REXO2 
RFK 
RG9MTD1 
RHBDD1 
RHOA 
RHOB 
RHOC 
RHOT1 
RHOT2 
RILP 
RMND1 
RNASEH1 
RNASEL 
RNF130 
RNMTL1 
ROBLD3 
ROMO1 
RPIA 
RPL10A 
RPL11 
RPL28 
RPL34 
RPL35A 
RPP14 
RPS6KA3 
RPS14 
RPS15A 
RPS18 
RPUSD4 
RRM2B 
RSAD1 
RTN4IP1 
SACS 
SAMM50 
SARDH 
SARS 
SARS2 
SCCPDH 
SCN5A 
SCO1 
SCO2 
SCP2 
SDHA 
SDHAF1 
SDHAF2 
SDHB 
SDHC 
SDHD 
SDSL 
SECISBP2 
SEPT4 
SERHL2 
SERPINA6 
SETX 
SF3B5 
SFTPB 
SFTPC 
SFXN1 
SFXN2 
SFXN3 
SFXN4 
SFXN5 
SGSH 
SH3BP5 
SH3GLB1 
SHC1 
SHMT1 
SHMT2 
SIL1 
SIRT3 
SIRT5 
SIRT7 
SLC1A3 
SLC2A2 
SLC3A1 
SLC6A19 
SLC6A20 
SLC7A3 
SLC7A7 
SLC7A14 
SLC9A6 
SLC12A7 
SLC13A2 
SLC16A1 
SLC17A5 
SLC19A2 
SLC22A4 
SLC22A5 
SLC25A1 
SLC25A2 
SLC25A3 
SLC25A4 
SLC25A5 
SLC25A6 
SLC25A10 
SLC25A11 
SLC25A12 
SLC25A13 
SLC25A14 
SLC25A15 
SLC25A16 
SLC25A17 
SLC25A18 
SLC25A19 
SLC25A20 
SLC25A21 
SLC25A22 
SLC25A23 
SLC25A24 
SLC25A25 
SLC25A26 
SLC25A27 
SLC25A28 
SLC25A29 
SLC25A30 
SLC25A31 
SLC25A32 
SLC25A33 
SLC25A34 
SLC25A35 
SLC25A36 
SLC25A37 
SLC25A38 
SLC25A39 
SLC25A40 
SLC25A41 
SLC25A42 
SLC25A43 
SLC25A44 
SLC25A45 
SLC25A46 
SLC27A3 
SLC30A6 
SLC35C1 
SLC36A2 
SLC37A4 
SLC46A1 
SLMO1 
SLMO2 
SMCP 
SMCR7L 
SMPD1 
SMPD2 
SNCAIP 
SND1 
SNPH 
SNRPN 
SOD1 
SOD2 
SPATA7 
SPATA19 
SPEF2 
SPG7 
SPINK5 
SPR 
SPRYD4 
SPTBN2 
SPTLC2 
SQRDL 
SSBP1 
STAR 
STARD3 
STARD4 
STARD5 
STAT5B 
STK19 
STOML1 
STOML2 
STS 
SUCLA2 
SUCLG1 
SUCLG2 
SUMF1 
SUOX 
SUPV3L1 
SURF1 
SYNE1 
SYNJ2BP 
TACO1 
TAP1 
TAPT1 
TARS 
TARS2 
TARSL2 
TAT 
TATDN3 
TAZ 
TBC1D21 
TBP 
TBRG4 
TCEB2 
TCIRG1 
TDP1 
TDRKH 
TEKT5 
TERT 
TFAM 
TFB1M 
TFB2M 
TGM2 
THEM4 
THEM5 
THG1L 
TIMM8A 
TIMM8B 
TIMM9 
TIMM10 
TIMM13 
TIMM17A 
TIMM17B 
TIMM22 
TIMM23 
TIMM44 
TIMM50 
TK2 
TMEM11 
TMEM14C 
TMEM14E 
TMEM22 
TMEM65 
TMEM66 
TMEM70 
TMEM85 
TMEM126A 
TMEM143 
TMEM147 
TMEM160 
TMEM186 
TMEM205 
TMEM223 
TMLHE 
TMTC1 
TOM1L2 
TOMM5 
TOMM7 
TOMM20 
TOMM22 
TOMM34 
TOMM40 
TOMM40L 
TOMM70A 
TOP1MT 
TP53 
TPI1 
TPMT 
TPO 
TPP1 
TRAP1 
TRAPPC2L 
TRAPPC4 
TRIAP1 
TRIM37 
TRIT1 
TRMT2B 
TRMU 
TRNT1 
TRPM6 
TSFM 
TSGA10 
TSHZ3 
TSPO 
TST 
TTBK2 
TTC19 
TTC32 
TTC35 
TTPA 
TTYH1 
TUFM 
TXN 
TXN2 
TXNDC6 
TXNRD1 
TXNRD2 
TYMP 
UBR5 
UCHL1 
UCP1 
UCP2 
UCP3 
UCRC 
UFC1 
UGT1A6 
UNG 
UPB1 
UQCC 
UQCR 
UQCRB 
UQCRC1 
UQCRC2 
UQCRFS1 
UQCRH 
UQCRQ 
UROS 
USMG5 
USP24 
USP30 
UXS1 
VAMP1 
VAMP8 
VARS2 
VAT1 
VDAC1 
VDAC2 
VDAC3 
VDR 
VPS25 
WARS2 
WASF1 
WBSCR16 
WBSCR28 
WFS1 
XDH 
XPNPEP3 
XYLB 
YARS2 
YME1L1 
YWHAE 
YWHAZ 
ZADH2 
ZBED5 
ZCCHC12 
ZNF607 
ZSWIM6 
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Table A-2. Variant details for molecular diagnoses and pVUS 
This table includes all prioritized variants in the 102 sequenced patients.  
  
Column descriptions for table below 
gene symbol Official gene symbol from NCBI 
chrpos Chromosome in GRCh37 assembly and position in chromosome. GrCh37 is similar to hg19 except 
that mitochondrial DNA is revised Cambridge Reference Sequence (CRS; Genbank NC_012920) 
rather than the chromosome displayed in the UCSC browser. 
REF Reference allele on + strand of GRCh37 reference genome.  Note indels are reported using the VCF 
format conventions. 
ALT Alternate allele on + strand, observed in patient. Note indels are reported using the VCF format 
conventions. 
variant type nSNP indicates nuclear single-nuclear variant, mtSNP indicates mtDNA single-nucleotide variant, 
indel indicates insertion/deletion 
position type CDS indicates coding sequence, utr3 indicates 3' UTR, utr5 indicates 5' UTR 
coding 
coordinate 
Coordinate of variant within coding region of transcript 
protein 
coordinate 
Coordinate of variant within protein region of transcript (# amino acids) 
transcript id Accession number of RefSeq or UCSC transcript 
strand Strand of transcript on reference assembly 
AF (1KG) Minor allele frequency of the variant, based on 1000 Genomes low-coverage whole-genome data 
(http://www.1000genomes.org/);missing value represents variant not present in 1KG 
AF (EVS_EA) Minor allele frequency of the variant in European Americans, based on the Exome Variant Server 
(January 2012) (http://evs.gs.washington.edu/EVS/); missing value represents variant not present in 
EVS 
AF (EVS_AA) Minor allele frequency of the variant in African Americans, based on the Exome Variant Server 
(January 2012) (http://evs.gs.washington.edu/EVS/); missing value represents variant not present in 
EVS 
AF (mtDB) Minor allele frequency of the mtDNA variant, based on mtDB (http://www.mtdb.igp.uu.se/); 
missing value represents variant not present in mtDB 
functional class Indicates nonsense, missense, synonymous, etc.  Includes evolutionary conservation of sites for 
missense variants (used for the "protein-modifying" filter) 
pathogenicity Predicted/known pathogenicity of variant 
PolyPhen2 Predicted consequence of nuclear variants using PolyPhen2 
(http://genetics.bwh.harvard.edu/pph2/bgi.shtml) with assembly=hg19, model=HumDiv, 
transcripts=Canonical, annotations=All 
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Table A-3: MitoExome sequencing statistics 
Median values per patient are shown with range across patients indicated in brackets (N=102). 
 
Targeted DNA Nuclear DNA mtDNA 
# gene loci 1589 37 
target size (bp) 2,297,893 16,569 
coverage   
mean coverage 226 [105-401] 12,680 [3,805-19,253] 
% targeted bp covered ≥1X 97 [95-98] 100 [100] 
% targeted bp covered ≥10X 95 [90-97] 100 [100] 
% targeted bp covered ≥20X 93 [88-96] 100 [100] 
# variants compared to reference DNA* 1521 [1427-1822] 55 [21-291] 
# rare variants 40 [23-94] 9 [0-51] 
# rare, likely deleterious variants 21 [11-40] 2 [0-10] 
# genes with 2 rare, likely deleterious variants 0 [0-3] NA 
* mtDNA variants: ≥ 1% heteroplasmy 
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Table A-4. Quantification of mtDNA heteroplasmy in patients with prior mtDNA diagnoses 
Percentages represent heteroplasmy levels derived from qPCR or from next-generation sequencing (NGS) 
read counts. Previously reported somatic mutations are indicated in bold (MITOMAP35). Abbreviations: LBL, 
lymphoblastoid cell line; MELAS, mitochondrial encephalomyopathy lactic acidosis and stroke-like episodes; 
MERRF, myoclonic epilepsy with ragged red fibers; hom., homoplasmic; het., heteroplasmic; nd, no data; 
KSS, Kearns-Sayre Syndrome ; NARP, Neuropathy, ataxia, and retinitis pigmentosa; 
 
    Observed heteroplasmy  
Patient 
ID 
Patient 
Dx 
OMIM 
# 
mtDNA 
mutation 
(Prior Dx) 
qPCR 
(Blood) 
qPCR 
(LBL) 
NGS 
(LBL) 
Other prioritized 
variants 
1107 MELAS 540000 m.3243A>G 37% 7% 2% - 
1110 MELAS 540000 m.3243A>G 47% 9% 4% 
m.3659G>A 2% 
(ND1:p.W118X); 
m.5260G>A 1% 
(ND2:p.W264X) 
1111 MELAS 540000 m.3243A>G 72% 52% 26% - 
1119* MELAS 540000 m.3243A>G 27% 3% 0.7% m.11866A>AC 16% (ND4:p.P370PfsX12) 
1120 MELAS 540000 m.3243A>G 37% 35% 14% m.4788G>A 2% (ND2:p.G107X) 
1122 MELAS 540000 m.3243A>G 39% 9% 3% m.15683C>T 1% (CYTB:p.Q313X) 
1123 MELAS 540000 m.3243A>G 14% 4% 2% - 
1108 MERRF 545000 m.8344A>G 14% 0% 1% - 
1116 MERRF 545000 m.8344A>G 53% 67% 91% - 
1121 MERRF 545000 m.8344A>G Hom nd 71% - 
1112 NARP 551500 m.8993T>G Hom nd 84% - 
1124 NARP 551500 m.8993T>C 97% nd 99% - 
1012 KSS 530000 m.3643_15569del Het nd 18% - 
* Variant not called by NGS pipeline due to heteroplasmy <1% 
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Table A-5. Prioritized variants of unknown significance (pVUS) in 84 patients without prior 
molecular diagnoses 
Prioritized variants (defined in Methods) are listed using Human Genome Variation Society (HGVS) 
nomenclature along with the patient genotype (hom., homozygous; het., heterozygous; hem., hemizygous; hp, 
heteroplasmy) and brief clinical description. Age represents age at diagnosis. Underline denotes established 
disease gene as in Figure 2.2. Variants separated by “+” are compound heterozygous. Variants separated by 
“,” are potential compound heterozygous (unphased). Genomic coordinates are in Table A-2.  
Abbreviations: DD, developmental delay; DM, diabetes mellitus; F, female; FTT, failure to thrive; GI, 
gastrointestinal; HL, hearing loss; HTN, hypertension; IUGR, intrauterine growth restriction; LD, Leigh's 
disease; M, male; mo, month-old; PDD, pervasive developmental delay; PEO, progressive external 
ophthalmoplegia; SNHL, sensoneural hearing loss; SS, short stature. 
a Variant present at 28% in maternal DNA 
b Not detected by Sanger sequencing in whole blood of patient or affected daughter  
c Patient harbored variant in POLG2 underlying diagnosis of PEO, see Table 2.1  
d Variant found to be hemizygous in an affected brother; other brother untested 
 
Patient 
ID Clinical description 
Prioritized variants of 
unknown significance (pVUS) 
1002 
57 yo M w/ PEO, ptosis, dysphagia, muscle weakness, exercise 
intolerance, mild HL HCCS:p.A174V (hem.) 
1003 17 yo F w/ LD, myopathy, migraine, exercise intolerance, SS, GI dysmotility ACACB:p.R830W+p.D1481V 
1007 58 yo M w/ myopathy, exercise intolerance, sleep disorder, GI dysmotility DNAI1:p.T48I+p.I682T 
1008 4 yo M w/ GI dysmotility, dyspnea, exercise intolerance, dysphagia, SS RNR1 m.1555A>G (3% hp)
a 
1011 
61 yo F w/ leukodystrophy, progressive dementia, gait difficulties, 
incontinent bladder and bowel; deceased; family history (sister 
and two daughters with leukodystrophy) 
COX1:p.G140X (42% hp)b 
COX2:p.W106X (16% hp)b 
1014 6 yo M w/ loss of skills, seizures, GI dysmotility, autonomic dysfunction COX2:p.W106X (1% hp) 
1015 5 yo F w/ PDD/Autism, GI dysmotility SECISBP2: p.M233I,p.N102MfsX23 
1019 c 53 yo F w/ bilateral ptosis, PEO, ataxia, fatigue, swallowing 
dysfunction;family history (3 siblings with PEO) 
RNASEH1:p.V142I+p.C148R 
1020 
3 mo F w/ FTT, microcephaly, encephalopathy, IUGR, 
hypotonia, pulmonary hypertension, heart failure; d. 3 mo; 
consanguinity (parents first cousins);  
family history (affected sister) 
ATP5A1:p.Y321C (hom.) 
HAO2:p.D259E (hom.) 
1025 17 yo F w/ myoclonus, myopathy, migraines, exercise intolerance, GI dysmotility POLG2:p.Q422P (het.) 
1026 33 yo F w/ myoclonic epilepsy, migraines, exercise intolerance, 
encephalopathy 
ANGEL2:p.P80S+p.Y68Xfs; 
MAN2B1:p.R613Q,p.D74E; 
POLG:p.G609S (het.) 
1032 23 yo M w/ brainstem stroke, lactic acidemia, SNHL, optic neuropathy, exercise intolerance 
NDUFAB1:p.D132Y (hom.) 
DPYD:p.T768K (hom.) 
          99 
1038 56 yo M w/ spastic paraparesis, optic atrophy, HL, bladder/bowel dysfunction, dysphagia RNR1 m.1494C>T (98% hp) 
1040 31 yo F w/ visual loss, myopathy, GI dysmotility, tachycardia, exercise intolerance AK8:p.N454S+p.R339C 
1044 51 yo F w/ myopathy, SNHL, sleep disorder, GI dysmotility/reflux, DM, autonomic dysfunction ACACA:p.E227K+c.1009-3T>G 
1046 37 yo F w/ retinopathy, SNHL, exercise intolerance, GI dysmotility, headache THG1L:p.A130T (hom.) 
1051 2 yo F w/ GI dysmotility, fatigue, dystonia, DD, hypotonia, 
stroke-like events, migraines 
ND1 m.3949T>C (3% hp) 
1067 30 yo F w/ ataxia, hypogonadotropic hypogonadism, hyperhidrosis, cognitive decline, migraine 
ETFB:p.T285M+p.V7F 
ABCB1:p.K624R+p.I221V 
POLG:p.L392V (het.) 
1072 20 yo F w/ migraines, exercise intolerance, GI dysmotility, autonomic dysfunction, myoglobinuria 
CERK:p.V338G (hom.) 
WFS1:p.D389E+p.C426Y 
1083 3 yo M w/ mild language delay, acute hypoxic encephalopathy APEX2:p.R141C (hem.) 
1085 53 yo F w/ DM, muscle weakness, exercise intolerance TRNL1 m.3271T>C (2% hp) 
1088 6 yo M w/ pseudo obstruction, glucose intolerance, B cell dysfunction, DD, SS MAOA:p.K520R (hem.) 
1091 
19 yo F w/ GI dysmotility, migraine, hypoplasia cerebellum, 
vision loss, LD, seizures, balance problems, autonomic 
dysfunction, hypotonia, immune deficiencies 
POLG:p.P163L (het.) 
1092 1 yo F w/ encephalopathy, vision loss, HL, myoclonus, dystonia, seizures, GI dysmotility; d. 1 yo ECH1:p.P269L,p.Y55C 
1100 15 yo F w/ GI dysmotility, cyclical vomiting, fatigue, exercise intolerance, headaches; family history (two affected brothers) NDUFA1:p.G32R (het.)
d 
1104 1 yo M w/ global DD, dystonia, GI dysmotility, migraines, seizures 
ACSL4:p.T227M (hem.); 
AIFM1:p.G53A (hem.); 
ASMTL:c.52-3G>C (het.) 
 
 
Table A-5 (continued) 
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Table A-6. Prior molecular diagnoses in nuclear DNA recovered by targeted exome sequencing 
Abbreviations: SANDO, sensory ataxia neuropathy dysarthria and ophthalmoplegia; MIRAS, mitochondrial 
recessive ataxia syndrome; PDHAD, Pyruvate dehydrogenase E1 alpha deficiency; het., heterozygous; hom., 
homozygous; cmpd het., compound heterozygous; Mol. Dx, molecular diagnosis 
 
Patient 
ID 
Previous 
diagnosis OMIM Gene Type 
Recovered mutations 
underlying Mol. Dx 
Other 
prioritized 
variants  
1117 
Mitochondrial 
Trifunctional 
Protein Deficiency 
609015 HADHA hom. c.180+3A>G - 
1118 SANDO 607459 POLG cmpd het. p.R852C +  [p.R627Q; p.G11D] 
RSAD1:p.R9C 
(hom.) 
1113 SANDO 607459 POLG cmpd het. p.G848S + p.A143V - 
1115 MIRAS 607459 POLG hom. p.A467T - 
1114 PDHAD 312170 PDHA1 hemizygous c.963_977dup21 - 
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Table A-7. Diagnostic yield in patient subsets 
Rate of molecular diagnosis (Mol. Dx) within five subsets of patients: (i) ETC activity ≤30% in any complex, 
normalized to citrate synthase, (ii) “Definite” Morava score, (iii) Infantile age of diagnosis ≤2 years, (iv) 
Family history, based on first-degree relative with same phenotype, and (v) Deceased status. Patients with 
molecular diagnoses included all those listed in Table 2.1, Table A-4, and Table A-6. P-value calculated with 
one-tailed binomial exact test relative to category “All” (first-row). Abbreviations: ns, not significant at 
p<0.01 
 
 
Patients without prior Mol. Dx 
(N=84) 
All patients 
(N=102) 
Category 
# Mol. Dx/ 
# in 
category 
% Mol. Dx P-value 
# Mol. Dx/ 
# in category 
% Mol. Dx P-value 
All 6/84 7%  24/102 24%  
ETC≤30% 3/52 6% ns 0/0 - - 
Definite 4/24 17% ns 8/28 29% ns 
Infantile 2/11 22% ns 0/0 - - 
Family history 3/6 50% <0.01 8/11 73% <0.01 
Deceased 2/5 40% ns 3/7 43% ns 
          102 
 
 
 
 
 
 
 
 
 
 
 
Figure A-1. Number of rare mtDNA variants in cases and controls  
(A) Mean number of rare mtDNA variants, defined as allele frequency (AF) <0.3% in mtDB and AF<10% in 
sequenced cases.  
(B) Mean number of ultra-rare mtDNA variants, defined as not present in mtDB and AF<2% in sequenced 
cases. 
MGH refers to 84 cases lacking previous molecular diagnoses. Ctrls refers to 284 European controls from 
1000 Genomes Project. Analysis limited to high heteroplasmy variants (at least 50% heteroplasmy based on 
read count) that are not known to cause disease (MITOMAP).  
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Figure A-2. Mutations in the KARS protein  
Schematic diagram depicts two splice isoforms of KARS protein that differ at the N-terminus, with 
coordinates above listed relative to mitochondrial isoform. Black text indicates mutations detected in patient 
1098, gray text indicates previously reported mutations.30 ClustalW2 multiple sequence alignment shown for 
each patient mutation; UniProt identifiers: Q15046, Q99MN1, Q5ZKP8, F1QSF6, Q8SXM8, Q22099, 
P15180, P0A8N5. Abbreviations: MTS, mitochondrial targeting sequence 
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Figure A-3. Number of variants in genes not previously linked to mitochondrial disease 
(A) Mean number of rare, likely deleterious, heterozygous variants.  
(B) Mean number of rare, likely deleterious, hemizygous, X-linked variants in males.  
(C) Mean number of autosomal genes containing rare, likely deleterious, recessive (i.e. homozygous or two 
heterozygous) variants. 
MGH refers to 84 cases lacking previous molecular diagnoses. Ctrls refers to 371 healthy individuals from the 
NIMH Control repository. Rare and likely deleterious are as defined in Methods. The relevant number of 
rare, synonymous variants is shown in each panel as a control. Analysis limited to MitoCarta genes not 
previously linked to mitochondrial disease. Asterisks indicate significance based on binomial exact test 
(*p<0.05, **p<0.01). Error bars represent standard error of the mean. 
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Figure A-4. Position of ATP5A1 patient mutation relative to yeast mgi  mutations 
Schematic of F1 ATPase 3D structure based on x-ray crystal structures of the bovine36 and yeast37 complexes. 
Red indicates position of the ATP5A1:p.Y321 residue in the alpha subunit (coordinates based on human 
precursor peptide). Zoomed inset shows that patient mutation (αY321) forms a H-bond with αD340 and is 
within 4Å of αY287, αQ317-αS325, αR330, αP338, αD340. Note αP331 and αA336 are known mgi 
mutation sites.11 These residues lie near the a-g interface and are thought to be important for coupling of the 
F1 and Fo sub-complexes.38 Visualization was performed using Pymol39 with coordinates of the bovine and 
yeast F1 ATPase (pdb, 1W0J and 2HLD). 
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Figure A-5. Molecular diagnoses and recessive candidates in two patient groups 
Comparison of MitoExome sequence results from our previous study6 and current study shows the fraction 
of patients with firm molecular diagnoses (dark blue) and autosomal recessive candidate genes (light blue). 
Comparison was limited to the 1,034 genes sequenced in both studies (thus excludes 212 DDx genes). Unlike 
Figure 2.4, this comparison shows all cases, including those with prior molecular diagnoses from traditional 
genetic testing.  
(A) Murdoch Childrens Research Institute (MCRI) cohort of 291 infantile patients with severe ETC defects6: 
124 with molecular diagnosis based on traditional sequencing, 38 with MitoExome sequencing, and 129 
without MitoExome sequencing. MitoExome sequence results were extrapolated from the 38 patients with 
MitoExome sequencing to the 129 patients without MitoExome sequencing. New diagnoses from the 
extrapolation were then added to 124 prior diagnoses.  
(B) 102 MGH patients: 18 with molecular diagnosis based on traditional sequencing (11 of which had 
diagnoses prior to referral to MGH), and 84 patients without prior molecular diagnosis (selected from a larger 
set of 159 patients as described in Methods). 
As a caveat, we note that different methods of ascertainment were used for each group. Future prospective 
studies will be required to explore differences in the genetic architecture between these two groups. 
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Figure A-6. Heteroplasmy of m.3243A>G across 7 patients with MELAS  
(A) Quantification of heteroplasmy based on qPCR versus next-generation sequencing (NGS) read-counts in 
the same LBL-derived DNA sample. 
(B) Quantification of heteroplasmy based on qPCR of DNA from whole blood versus lymphoblastoid cell 
line (LBL). 
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